Research Paper

Lifetime depression and age-related changes in body composition, cardiovascular function, grip strength and lung function: sex-specific analyses in the UK Biobank

Julian Mutz¹, Cathryn M. Lewis^{1,2}

¹Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, Greater London SE5 8AF, United Kingdom ²Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, Greater London SE1 9RT, United Kingdom

Correspondence to: Julian Mutz; email: julian.mutz@gmail.com, https://orcid.org/0000-0001-5308-1957Keywords: aging, body composition, cardiovascular function, depression, grip strengthReceived: April 8, 2021Accepted: June 19, 2021Published: July 7, 2021

Copyright: © 2021 Mutz and Lewis. This is an open access article distributed under the terms of the <u>Creative Commons</u> <u>Attribution License</u> (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Individuals with depression, on average, die prematurely, have high levels of physical comorbidities and may experience accelerated biological ageing. A greater understanding of age-related changes in physiology could provide novel biological insights that may help inform strategies to mitigate excess mortality in depression. We used generalised additive models to examine age-related changes in 15 cardiovascular, body composition, grip strength and lung function measures, comparing males and females with a lifetime history of depression to healthy controls. The main dataset included 342,393 adults (mean age = 55.87 years, SD = 8.09; 52.61% females). We found statistically significant case-control differences for most physiological measures. There was some evidence that age-related changes in body composition, cardiovascular function, lung function and heel bone mineral density followed different trajectories in depression. These differences did not uniformly narrow or widen with age and differed by sex. For example, BMI in female cases was 1.1 kg/m² higher at age 40 and this difference narrowed to 0.4 kg/m² at age 70. In males, systolic blood pressure was 1 mmHg lower in depression cases at age 45 and this difference widened to 2.5 mmHg at age 65. These findings suggest that targeted screening for physiological function in middle-aged and older adults with depression is warranted to potentially mitigate excess mortality.

INTRODUCTION

Individuals with mental disorders, on average, die prematurely [1] and have high levels of physical comorbidities [2]. Although it is almost universally accepted that health deteriorates as part of the normal ageing process, there is substantial variation in ageing trajectories [3]. Up to a third of older adults experience depression and in many cases show greater levels of functional decline and cognitive impairment [4].

To better understand the heterogeneity in ageing trajectories, it would be useful to objectively assess

whether groups or individuals deviate from 'normal' age-related changes. To date, no single biological marker that fully captures the ageing process has been discovered, although several candidate measures such as telomere attrition have been described [5]. The measurement of blood-based biomarkers such as leukocyte telomere length is minimally invasive, relatively costly and time-consuming, especially at population scale. Magnetic resonance imaging, for instance used to derive estimates of brain age [6], is costly and less accessible. Physiological measures such as hand-grip strength can be easily obtained, provide reliable information about age-related functional decline and predict morbidity and mortality risk [7–9].

Several studies have examined age-related variation in these measures [10–12]. However, less is known about the ageing trajectories of individuals with depression and whether similar patterns are observed across different physiological measures. A deeper understanding of age-related changes in physiology in individuals with depression might provide insights into the premature mortality observed in mental disorders and could point towards potential targets for prevention or intervention of accelerated ageing [13].

The aim of this study was to examine associations between age and multiple physiological measures, and to test for differences in these measures between middle-aged and older adults with a lifetime history of depression and healthy controls across age. Given major sex differences in physiology, age-related diseases and life expectancy [14], and in prevalence of depression [15], analyses were conducted separately in males and females. In a separate study, we have examined agerelated changes in physiology in bipolar disorder [16].

Using data from up to ~342,000 UK Biobank participants aged 37-73, the following research questions were examined for each physiological measure assessed during the baseline assessment: Are there average differences between males and females with lifetime depression and healthy controls? Do age-related changes differ between males and females with lifetime depression and healthy controls?

RESULTS

Study population

Of the 502,521 UK Biobank participants, 392,467 (78.1%) individuals had complete data on all covariates. We yielded an analytical sample of 342,393 adults after excluding individuals who did not meet our inclusion criteria or whose lifetime depression status could not be determined. Sample sizes for physiological measures that were available in subsets of the UK Biobank population ranged from 120,843 to 224,805 participants (Figure 1).

Sample characteristics

The average age of participants in our main dataset was 55.87 years (SD = 8.09) and 52.61% of participants were female. About 22.25% of participants (n = 87,339) met criteria for lifetime depression, 64.43% (n = 56,276) of whom were female. Descriptive statistics and density plots of the physiological measures stratified by sex and lifetime depression status are presented in Table 1 and Supplementary Material 5, respectively. Descriptive statistics of the covariates are presented in Supplementary Material 6.



Figure 1. Flowchart of study population. The main dataset included hand-grip strength, blood pressure, pulse rate and measures of body composition.

Table 1. Physiological measures.

	Overall	Fen	nale	Ma		
	(N=502521)	Healthy control (N=123842)	Depression (N=56276)	Healthy control (N=131212)	Depression (N=31063)	
Hand-grip strength						
Mean (SD)	31.77 (11.34)	25.10 (6.46)	24.73 (6.67)	41.34 (9.09)	40.37 (9.37)	
Missing	3203					
Systolic blood pressure						
Mean (SD)	137.87 (18.65)	135.07 (19.20)	132.32 (18.28)	141.11 (17.38)	139.02 (16.78)	
Missing	1325					
Diastolic blood pressure						
Mean (SD)	82.26 (10.15)	80.63 (9.98)	80.26 (9.93)	84.19 (9.96)	83.78 (10.02)	
Missing	1323		× ,	× ,		
Pulse rate						
Mean (SD)	69.42 (11.26)	69.83 (10.38)	70.05 (10.52)	67.74 (11.59)	68.70 (11.99)	
Missing	1323	09.05 (10.50)	(10.02)	0/1/ (11.09)	00.70 (11.99)	
Body mass index	1525					
Mean (SD)	27.43 (4.80)	26.63 (4.86)	27.35 (5.39)	27.62 (4.01)	28.08 (4.45)	
Missing	3105	20.03 (4.00)	21.33 (3.37)	27.02 (1.01)	20.00 (1.13)	
Body fat percentage	5105					
Mean (SD)	31.45 (8.55)	35.98 (6.77)	36.87 (7.02)	24.93 (5.63)	25 55 (5 88)	
Missing	10408	55.98 (0.77)	50.87 (1.02)	24.93 (5.03)	25.55 (5.88)	
Fat mass	10408					
	24.96 (0.57)	26.12 (9.55)	27(7(10(0)))	21.95(7.97)	22.99(9.71)	
Mean (SD)	24.86 (9.57)	20.12 (9.55)	27.67 (10.60)	21.85 (7.87)	22.88 (8.71)	
Missing	10973					
Sat-free mass	52.00 (11.50)	44.42 (4.95)	45.05 (5.17)		(1.25 (7.02)	
Mean (SD)	53.22 (11.50)	44.43 (4.85)	45.05 (5.17)	63.74 (7.61)	64.25 (7.93)	
Missing	10176					
Waist-hip ratio						
Mean (SD)	0.87 (0.09)	0.81 (0.07)	0.82 (0.07)	0.93 (0.06)	0.94 (0.07)	
Missing	2265					
		N=43133	N=19146	N=52359	N=12177	
Peak expiratory flow						
Mean (SD)	407.82 (130.78)	355.08 (76.97)	359.35 (76.98)	511.67 (115.38)	509.05 (117.30)	
Missing	168566					
Forced expiratory volume 1s						
Mean (SD)	2.85 (0.78)	2.50 (0.53)	2.53 (0.53)	3.45 (0.73)	3.43 (0.75)	
Missing	149197					
Forced vital capacity						
Mean (SD)	3.78 (0.98)	3.28 (0.64)	3.31 (0.64)	4.59 (0.88)	4.57 (0.90)	
Missing	149197					
FEV ₁ / FVC						
Mean (SD)	0.75 (0.07)	0.76 (0.06)	0.76 (0.06)	0.75 (0.07)	0.75 (0.07)	
Missing	149197					
-		N=85994	N=31736	N=89790	N=17285	
Heel bone mineral density						
Mean (SD)	0.54 (0.14)	0.52 (0.12)	0.52 (0.12)	0.58 (0.15)	0.57 (0.15)	
Missing	180831	····=(-··=)	/		(0.20)	
	100001	N=38592	N=25073	N=42889	N=14289	
Arterial stiffness		11-30372	11-23073	11-12007	11-17207	
Mean (SD)	9 34 (4 05)	8 70 (4 41)	871 (3 27)	9.01 (1.27)	9.97 (3.30)	
	9.34 (4.05)	8.70 (4.41)	8.71 (3.27)	9.91 (4.27)	9.97 (3.30)	
Missing	332721					

Note: SD, standard deviation; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

Sex differences

We found moderate to large sex differences across all physiological measures. Female participants, on average, had lower hand-grip strength, systolic and diastolic blood pressure, BMI, fat-free mass, waist-hip ratio, peak expiratory flow, FEV₁, forced vital capacity, heel bone mineral density and arterial stiffness than males. Their pulse rate, body fat percentage, fat mass and FEV₁/FVC ratio were higher than in males (Table 2).

Case-control differences

We also found statistically significant differences between individuals with lifetime depression and healthy controls for most measures. Females with lifetime depression, on average, had lower hand-grip strength and lower blood pressure. Their pulse rate, BMI, body fat percentage, fat mass, fat-free mass, waist-hip ratio, peak expiratory flow, FEV₁, forced vital capacity and FEV₁/FVC ratio were higher compared to healthy controls. We did not find evidence of differences in heel bone mineral density or arterial stiffness between female cases and controls. Males with lifetime depression had lower hand-grip strength, blood pressure, peak expiratory flow, FEV1, forced vital capacity and heel bone mineral density, while their pulse rate, BMI, body fat percentage, fat mass, fat-free mass and waist-hip ratio were higher. We did not find evidence that the FEV₁/FVC ratio or arterial stiffness differed between males with lifetime depression and healthy controls. The differences between individuals with lifetime depression and healthy controls were small, with the largest effect size corresponding to a standardised mean difference of 0.16 (95% CI 0.15-0.17) for fat mass in females (Table 3).

Age-related physiological changes

Results from the unadjusted GAMs suggested that hand-grip strength, fat-free mass, lung function and heel bone mineral density declined with age, while systolic blood pressure, body fat percentage, fat mass, waist-hip ratio and arterial stiffness increased with age. Nonlinear associations with age were most evident for diastolic blood pressure, pulse rate and BMI. For example, diastolic blood pressure increased until about age 55 and decreased thereafter. BMI increased with age until participants were in their mid to late 50s and plateaued thereafter, except in healthy females where BMI increased until age 70 (Figures 2, 3).

Case-control differences in age-related physiological changes

Age-related changes in blood pressure, pulse rate, body composition and heel bone mineral density followed distinct trajectories in females with lifetime depression and healthy controls (Figure 4). There was also evidence of differences in age-related changes in handgrip strength, blood pressure, pulse rate, lung function and heel bone mineral density between males with lifetime depression and healthy controls (Figure 5).

In females, we obtained similar results after adjustment for covariates, although differences between cases and controls were attenuated and there was greater overlap in the trajectories of pulse rate, lung function and heel bone mineral density. We found no evidence that age-related changes in arterial stiffness differed between female cases and controls (Supplementary Material 7A). We also obtained similar results after adjustment for covariates in males, with some attenuation of differences between cases and controls (Supplementary Material 7B). The formal statistical tests for differences in age-related changes in hand-grip strength and heel bone mineral density were no longer statistically significant, although age-related changes in forced vital capacity and FEV_1 differed between male cases and controls.

Sensitivity analyses

Case-control numbers for the sensitivity analyses are presented in Supplementary Material 8A. We retained between 35.15% to 45.97% of cases and 100% of controls in the analyses in which cases included only those with lifetime depression according to at least two different measures. In the analyses in which we restricted our sample to participants with lifetime depression status assessed using the CIDI-SF, we retained between 24.69% to 40.67% of cases and between 22.58% to 28.03% of controls.

We found similar results when we applied more stringent criteria for lifetime depression. Average differences between female cases and controls were slightly larger for all physiological measures. In males, differences were also larger, except that there was no evidence of differences in lung function between cases and controls (Supplementary Material 8B). Most results were also similar when we restricted our analyses to individuals with lifetime depression status assessed using the CIDI-SF. In females, differences were slightly larger, except for hand-grip strength, and there was no evidence of differences in diastolic blood pressure. In males, there was no evidence that hand-grip strength or diastolic blood pressure differed between cases and controls, and differences in lung function measures were reversed (although there was no evidence of differences in peak expiratory flow or the FEV₁/FVC ratio). Average differences in body composition, systolic blood pressure and pulse rate were slightly larger, while differences in heel bone mineral density were slightly smaller (Supplementary Material 8B).

Variable	SMD	9	95% CI
Hand-grip strength	-2.051	-2.060	-2.043
Systolic blood pressure	-0.358	-0.364	-0.351
Diastolic blood pressure	-0.361	-0.368	-0.354
Pulse rate	0.179	0.172	0.186
Body mass index	-0.185	-0.191	-0.178
Body fat percentage	1.771	1.763	1.779
Fat mass	0.502	0.496	0.509
Fat-free mass	-3.006	-3.016	-2.997
Waist-hip ratio	-1.775	-1.782	-1.767
Peak expiratory flow	-1.569	-1.582	-1.557
Forced expiratory volume 1s	-1.460	-1.473	-1.448
Forced vital capacity	-1.674	-1.687	-1.661
FEV ₁ / FVC	0.165	0.154	0.176
Heel bone mineral density	-0.397	-0.405	-0.388
Arterial stiffness	-0.304	-0.315	-0.292

Table 2. Sex differences in physiological measures (females compared to males).

Note: SMD, standardised mean difference; CI, confidence interval; FEV_1 , forced expiratory volume in one second; FVC, forced vital capacity. All Bonferroni-adjusted *p*-values for Welch's t-test < 0.001. Negative values correspond to lower values in females.

V	Female					Male				
Variable	SMD	95%	6 CI	$p_{\mathrm{Bonf.}}$	$p_{\rm BH}$	SMD	95%	6 CI	p _{Bonf.}	<i>р</i> вн
Hand-grip strength	-0.056	-0.066	-0.046	< 0.001	< 0.001	-0.106	-0.118	-0.093	< 0.001	< 0.001
Systolic blood pressure	-0.145	-0.155	-0.135	< 0.001	< 0.001	-0.121	-0.133	-0.108	< 0.001	< 0.001
Diastolic blood pressure	-0.037	-0.047	-0.028	< 0.001	< 0.001	-0.041	-0.053	-0.028	< 0.001	< 0.001
Pulse rate	0.022	0.012	0.032	< 0.001	< 0.001	0.083	0.070	0.095	< 0.001	< 0.001
Body mass index	0.144	0.134	0.154	< 0.001	< 0.001	0.112	0.100	0.124	< 0.001	< 0.001
Body fat percentage	0.129	0.119	0.139	< 0.001	< 0.001	0.111	0.098	0.123	< 0.001	< 0.001
Fat mass	0.156	0.146	0.166	< 0.001	< 0.001	0.129	0.117	0.141	< 0.001	< 0.001
Fat-free mass	0.124	0.114	0.134	< 0.001	< 0.001	0.066	0.053	0.078	< 0.001	< 0.001
Waist-hip ratio	0.090	0.080	0.100	< 0.001	< 0.001	0.138	0.126	0.151	< 0.001	< 0.001
Peak expiratory flow	0.055	0.038	0.072	< 0.001	< 0.001	-0.023	-0.042	-0.003	0.382	0.032
Forced expiratory volume 1s	0.051	0.034	0.068	< 0.001	< 0.001	-0.024	-0.044	-0.005	0.241	0.022
Forced vital capacity	0.046	0.029	0.063	< 0.001	< 0.001	-0.022	-0.042	-0.003	0.421	0.032
FEV ₁ / FVC	0.018	0.001	0.035	0.569	0.044	-0.011	-0.031	0.009	>0.999	0.276
Heel bone mineral density	0.013	-0.0001	0.026	0.789	0.056	-0.077	-0.093	-0.061	< 0.001	< 0.001
Arterial stiffness	0.004	-0.012	0.020	>0.999	0.571	0.015	-0.004	0.034	>0.999	0.078

Table 3. Differences in physiological measures between individuals with lifetime depression and healthy controls.

Note: SMD, standardised mean difference; CI, confidence interval; Bonf, Bonferroni; BH, Benjamini and Hochberg; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity. *P*-values for Welch's t-test. Negative values correspond to lower values in depression cases.

Differences in age-related changes in physiological measures between female cases and controls were similar to those observed in our main analyses (Supplementary Material 8C). There was less evidence that age-related changes in systolic blood pressure differed between males with lifetime depression according to CIDI-SF and healthy controls. There was also some evidence that agerelated changes in body composition followed slightly different trajectories in males with lifetime depression according to CIDI-SF, and there was more overlap in the lung function trajectories (Supplementary Material 8D).

DISCUSSION

We used data from the UK Biobank to examine differences in 15 physiological measures, between

males and females, and between lifetime depression cases and healthy controls. The large sample size enabled us to highlight subtle differences between cases and controls, with heterogenous findings from previous studies that were often limited by small sample sizes. We demonstrate that case-control differences for several physiological measures vary by age, providing additional insights into the heterogeneity in ageing trajectories observed in individuals with a lifetime history of depression.

Principal findings

We observed moderate to large sex differences across all physiological measures. We also found small but statistically significant differences between lifetime



Figure 2. Generalised additive models of age-related changes in physiological measures in females with lifetime depression and healthy controls. The solid lines represent physiological measures against smoothing functions of age. The shaded areas correspond to approximate 95% confidence intervals ($\pm 2 \times$ standard error). FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

depression cases and healthy controls for most measures. All physiological measures varied with age, and we observed several differences between the trajectories of depression cases and controls. Agerelated changes in body composition differed between female cases and controls, while changes in cardiovascular function differed between cases and controls of both sexes. There was some evidence of differences in the heel bone mineral density trajectories of both sexes, although in males only prior to adjustment for covariates. We found some evidence that age-related changes in lung function differed between male cases and controls after adjustment for covariates. Differences between cases and controls did not uniformly narrow or widen with age. For example, BMI in female cases was 1.1 kg/m^2 higher at age 40 and this difference



Figure 3. Generalised additive models of age-related changes in physiological measures in males with lifetime depression and healthy controls. The solid lines represent physiological measures against smoothing functions of age. The shaded areas correspond to approximate 95% confidence intervals ($\pm 2 \times$ standard error). FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

narrowed to 0.4 kg/m^2 at age 70. In male cases, systolic blood pressure was 1 mmHg lower at age 45 and this difference widened to 2.5 mmHg at age 65.

Findings in the context of other studies

Sex differences

We confirm previous research on sex differences in hand-grip strength [10, 17–19], blood pressure [20],

pulse rate [21, 22], lung function [23–25], body fat percentage [26, 27], fat-free mass [26, 27] and waist-hip ratio [28]. Our finding that BMI was higher in males confirms findings from a German study [28], although studies in US and Chinese adults found no evidence of sex differences [26, 27]. The observation that fat mass was higher in females confirms findings from Sweden [29] and the US [26], although research in Chinese adults found no evidence of sex differences [27]. Males





had higher heel bone mineral density, supporting previous studies of hand [30] and heel [31] bone mineral density. Our finding that arterial stiffness was higher in males supports a review which found greater arterial stiffness in males until at least age 60 [32]. However, most studies included in another systematic review found no evidence of sex differences [33], and some studies found higher arterial stiffness in females [34–36].

Age-related physiological changes

Our findings confirm previous research on age-related changes in hand-grip strength [10, 18, 19], blood pressure





[12, 20, 37, 38], fat mass [26, 29, 39], fat-free mass [26, 39, 40], waist-hip ratio [28], lung function [23–25, 41], bone mineral density [30, 42] and arterial stiffness [21, 34]. In males, we observed a small increase in pulse rate until age 55 and a decrease thereafter, similar to data from activity trackers in >90,000 US adults [22]. However, we found a slight decrease in pulse rate in females until their mid 50s and an increase thereafter. Although we observed some increase in BMI with age, comparable to results from Swedish cohorts [29], Chinese research found no evidence of age-related changes in BMI [27]. Our finding that body fat percentage increased with age confirms previous studies [29, 40], although we found limited evidence of a plateau or decrease before age 70 observed in previous research [26].

Sex differences in age-related physiological changes

We confirm previous studies on sex differences in agerelated changes in hand-grip strength [17, 18], blood pressure [12, 20, 37], lung function [24, 41] and bone mineral density [30, 42]. In contrast to observations that pulse rate followed parallel ageing trajectories in both sexes [22], we found changes in pulse rate in females were mirrored by inverse changes in males.

Differences in BMI narrowed with age as BMI plateaued in males at age 50 and slightly decreased thereafter, while it increased in females until at least age 65. Greater age-related increase in BMI in females has been observed previously [29]. Body fat percentage followed similar trajectories with age in both sexes. However, research in Chinese adults suggested that body fat percentage plateaued in males over 40 and continued to increase in females [27], while results from the US showed that body fat percentage decreased in females and males over 55 and 65, respectively [26]. Although Swedish data showed slightly greater age-related increase in fat mass in females [29], we found similar trajectories in both sexes. Our finding that fat mass plateaued earlier in females confirms research in US adults [26]. However, research in Chinese adults found that fat mass remained stable in males from age 40 but continued to increase in females [27]. Our study did not support the finding that fat-free mass decreased earlier in females than in males [29]. Fat-free mass decreased in both sexes, with steeper decline in males. Our finding that waist-hip ratio increased linearly with age in females confirms observations from China [43], but we did not find that waist-hip ratio plateaued in males at age 50 and decreased thereafter. Instead, we found that waist-hip ratio continued to increase until age 70. This increase attenuated at old age, in line with German research [28]. The difference between the trajectories of males and females had an inverted

U-shape, with the largest difference in waist-hip ratio between age 50 to 55.

We examined absolute changes in lung function. However, a review of longitudinal studies concluded that although there was a steeper decline in absolute lung function in males, evidence of sex differences in relative decline in lung function was limited [41]. Limited previous research examined sex differences in age-related changes in the FEV₁/FVC ratio. We found that the difference in the FEV₁/FVC ratio narrowed with age, with some variation at the lower and upper age range.

Finally, we found only limited evidence of a steeper age-related increase in arterial stiffness in males (in our study until the age of 50) as suggested by previous studies [21, 36], or that females over 65 had higher arterial stiffness than males [32]. Sex differences in arterial stiffness narrowed between age 60 and 70.

Case-control differences

Our finding that hand-grip strength was lower in individuals with lifetime depression confirms previous research [44–47]. Although several studies found stronger associations between hand-grip strength and depression in females [44, 48, 49] or no sex differences [45], we observed larger differences between male cases and controls. Results from the Northern Finland 1966 birth cohort suggested that low hand-grip strength was associated with increased depressive symptoms only in males [50], while in the Irish Longitudinal Study of Ageing higher hand-grip strength was associated with lower incident depression only in females [44].

The finding that cases had lower blood pressure confirms results from the Norwegian HUNT study [51, 52]. Although several studies found lower blood pressure in depression [51–54], other research found no evidence of differences in blood pressure [55] and a meta-analysis found higher incident hypertension in depression [56]. A 2-year follow-up study suggested that low blood pressure constitutes a risk factor for depression [57]. We confirmed previous analyses showing higher pulse rate in depression [58–60].

All body composition measures were elevated in cases. A meta-analysis of observational studies found an increased risk of obesity in depression [61], and findings from the 1958 British Birth Cohort found associations between depression and both underweight and obesity [62]. Previous studies of BMI and depression yielded mixed results, including higher BMI [63], lower BMI [64, 65], U-shaped association [66] or no association [67]. A Mendelian randomisation study suggested that BMI was a causal risk factor for depression but not vice versa [68]. Mixed results have also been observed for waist-hip ratio, including lower risk of depressive symptoms in older females with high waist-hip ratio [65] and associations between depression and high waist-hip ratio [63, 69]. An analysis of UK Biobank participants found that females with probable depression had higher waist-hip ratio than males [70], although other research found higher waist-hip ratio in males with depression but not in females [71], or no evidence of an association with depressive symptoms [64]. Previous research found no evidence of associations between depression and total fat or lean mass, although central fat mass and lean mass were lower amongst older females with depression [72]. A Mendelian randomisation study suggested that fat mass. but not fat-free mass, was a causal risk factor for depression [68]. Although we found higher body fat percentage in cases, a recent analysis found associations between depression and higher body fat percentage only females, participants in although were aged 90 years [73].

In contrast to results from the Netherlands Study of Anxiety and Depression (NESDA) which suggested that peak expiratory flow was lower in females and higher in males with depression [74], we found higher peak expiratory flow in female cases. Male cases had lower peak expiratory flow, although not across all analyses. We found similar results for FEV_1 , forced vital capacity and FEV₁/FVC ratio. Differences between male cases and controls were usually not observed in the sensitivity analyses, except that FEV_1 and forced vital capacity were higher in the subset of male cases classified according to CIDI-SF than in controls. Research in Germany found lower FEV₁ in depression but no evidence of differences in forced vital capacity or FEV₁/FVC ratio [75]. Data from a community-based cohort in Korea suggested that FEV₁, forced vital capacity and FEV₁/FVC ratio were lower in depression, although only FEV1 remained lower after adjustment for covariates [76]. However, a prospective study found that lower forced vital capacity and FEV_{0.75} were associated with more depressive symptoms at follow-up in middle aged and older males [77].

We found that heel bone mineral density was lower in male cases, consistent with most previous studies [78]. There was some evidence that heel bone mineral density was higher in female cases in sensitivity analyses, contrary to most previous studies. A meta-analysis of 14 studies showed that spine and hip bone mineral density were lower in depression, especially in females [79]. One previous study suggested that heel bone mineral density was lower in female cases below the age of 40 but not in older females [80], although another study found lower heel bone mineral density also in postmenopausal females [81]. We did not find evidence that arterial stiffness differed between cases and controls. This finding contrasts with most previous studies that found higher arterial stiffness in depression [82, 83], including a recent UK Biobank study [84].

Case-control differences in age-related physiological changes

Hand-grip strength differences between female cases and controls were fairly stable across age, while generally narrowing with age in males. To our knowledge, the only study that examined changes in hand-grip strength in depression longitudinally found similar rates of decline in female cases and controls, in line with our findings. Contrary to our study, the authors found no evidence that hand-grip strength decreased in male cases [85].

The HUNT study showed that prospective associations between depressive symptoms and changes in blood pressure were independent of age [51]. Findings from the Baltimore Longitudinal Study of Aging found associations between greater levels of depressive symptoms and lower diastolic blood pressure until age 45, and attenuated age-related decline thereafter in females but not in males [86]. We found that casecontrol differences in systolic blood pressure increased with age. There was no evidence of a difference in diastolic blood pressure until participants were in their early to mid 50s, although diastolic blood pressure was lower in cases thereafter. This difference narrowed as participants approached age 70. To our knowledge, this is the first study to show that differences in pulse rate between cases and controls narrowed with age.

This is also the first study to examine age-related changes in body composition in cases compared to controls. Across these measures, we found that differences in body composition narrowed with age in females, while generally remaining constant in males. There were some inconsistencies in the sensitivity analyses with more stringent case definition. These analyses suggested an increasing difference in body fat percentage, a flat inverted U-shape for fat mass and fatfree mass, and some variation in the difference smooth for wait-hip ratio.

Results from the NESDA suggested a steeper decrease in peak expiratory flow in male cases during a 6-year follow-up, while rates of decline were similar in female cases and controls [85]. We also found some evidence of a steeper decrease in peak expiratory flow with age in male cases, although differences between female cases and controls remained stable. Rates of decline in the NESDA were similar in younger and older participants [85], concordant with our results showing an almost linear decrease in peak expiratory flow. While one previous study found a weak negative correlation between depressive symptoms and FEV₁ only in participants older than 50 [76], our study is, to our knowledge, the first to examine case-control differences in ageing trajectories across multiple lung function measures. We found that the difference in FEV₁ and forced vital capacity remained stable with age in females, with some variation in sensitivity analyses, while the difference widened with age in males, although not across all analyses. We did not find clear evidence of differences in the trajectories of FEV₁/FVC ratio.

Differences in heel bone mineral density between cases and controls narrowed with age, approaching no difference in males in their late 60s and in females in their mid 50s, with some evidence of higher bone mineral density in older females. One previous study found lower heel bone mineral density in females with depression who were younger than 40 but not in older females [80]. However, lower bone mineral density has also been found in postmenopausal females with depression [87]. A meta-analysis of 23 studies found lower bone mineral density in the spine, hip and forearm in premenopausal than in postmenopausal female cases compared to controls [88]. Our finding that differences in bone mineral density narrowed with age differs from a meta-analysis of five longitudinal studies which suggested that depression was associated with increased annual loss in hip and spine bone mineral density [79]. One study showed that elderly females with higher levels of depressive symptoms had an age-adjusted mean total hip bone mineral density decrease of 0.96% per year, compared to 0.69% in females with fewer symptoms [89]. Similar findings have been observed in males [90]. However, a prospective study of premenopausal females found no evidence of decreasing bone mineral density irrespective of depressive symptoms [91]. To our knowledge, this is the first study to examine differences in age-related changes in arterial stiffness between cases and controls. While we did not find clear evidence of different trajectories with age, there was some evidence that arterial stiffness was higher in female cases younger than age 50.

Inconsistencies between studies could result from variation in sample characteristics, differences in assessment and definition of depression, or medication use. For example, previous research found that after adjustment for depression, antidepressant use was associated with lower spine bone mineral density in females but not in males [92], or that depression was associated with lower systolic blood pressure, while antidepressant use was associated with higher systolic and diastolic blood pressure [54]. Inconsistencies could also reflect differences in prevalence of specific symptoms. For example, somatic/vegetative symptoms but not mood/cognitive symptoms were previously associated with higher waist-hip ratio [69].

Differences between cases and controls could reflect disease-related processes or poor underlying health status [93] occurring more frequently in cases. They could also result from biological mechanisms affecting depression and physiology (although a recent study did not find evidence of genetic correlations between depression and body composition [94]), or from treatment-related changes, for example lower bone mineral density due to antidepressant use [92]. Behavioural factors such as unhealthy lifestyles known to affect physiology (e.g., smoking and low levels of physical activity) might also contribute. It is likely that associations between depression and physiology are bidirectional in that depression is both cause and consequence of poor physiology [87]. Sex differences might be due to the relative frequency of different symptoms experienced by males and females or differences in prevalence of comorbidities.

Weaknesses of the study

Our research inevitably has limitations. Although we briefly remarked on this above, our analyses provide limited insights into the mechanism underpinning our results. The cross-sectional nature of our study presents additional uncertainty about whether these findings reflect changes in physiology due to ageing or cohortspecific differences in these measures and confounding factors. For example, previous research suggested that hand-grip strength is lower in younger cohorts [19], which could result in underestimating age-related decline in our study. Research on frailty indices provided evidence of stability across birth cohorts [95] as well as higher levels of frailty in more recent cohorts [96, 97]. The finding that some physiological differences narrowed with age could result from selection bias leading to older participants with depression in our study being healthier, relative to their age group, than younger participants. Selection bias resulting in healthier older adults participating in the UK Biobank at higher rates could also result in underestimating age-related changes. Finally, some concerns remain about the validity and reliability of our definition of lifetime depression [98]. To maximise the sample size available for our main analyses, we classified cases using multiple data sources. However, these sources all have specific strengths and limitations, which have been discussed in detail elsewhere [98-100]. For example, mental disorders are likely

underreported in linked health records. Self-reports might contain some level of misclassification because mental disorders are heterogenous in their presentation and have fuzzy boundaries, although participants were asked to only report diagnoses made by health professionals. To address these concerns, we conducted sensitivity analyses with more stringent case definition and found comparable results. Given that mental disorders fluctuate throughout the life course, we examined lifetime depression, which includes single episode and recurrent depression. Future studies could examine differences between single episode and recurrent depression as well as changes in physiology in relation to current psychiatric status at a more fine-scale timespan longitudinally.

Generalisability

The overall response rate of the UK Biobank was low (5.5%) and compared with non-responders, participants were older, more often female, of higher socio-economic status and reported fewer health conditions compared with data from a nationally representative survey [101]. An empirical investigation comparing the UK Biobank with data from 18 cohort studies with conventional response rates found the direction of associations to be similar, although with differences in magnitude [102]. There are additional concerns about the representativeness of individuals with mental disorders because participation in research can be influenced by selection bias due to mental health [103]. Our findings might not generalise to younger and older populations and conclusions are limited to adults between the ages of 37 to 73. Additional studies including children and adolescents as well as the elderly are needed.

Implications

The primary aim of this study was to examine differences in age-related physiological changes between individuals with lifetime depression and healthy controls. Understanding age-related changes in physiology in individuals with depression is of public health importance, given that variation in these measures is linked to morbidity, mortality and other functional outcomes. The differences observed between cases and controls suggest that targeted screening for physiological function middle-aged and older adults with depression is warranted to potentially mitigate excess mortality. Future studies aimed at further disentangling aetiology are needed to inform preventative and treatment strategies. Interventions such as resistance training might help improve physiological health and reduce depressive symptoms [104], although multiple factors associated with health status should be considered [105].

MATERIALS AND METHODS

Study population

The UK Biobank is a prospective study of >500,000 UK residents aged 37-73 at baseline, recruited between 2006–2010. Details of the study rationale and design have been reported elsewhere [106]. Briefly, individuals registered with the UK National Health Service (NHS) and living within a 25-mile (~40 km) radius of one of 22 assessment centres were invited to participate (9,238,453 postal invitations sent). Participants provided information on their sociodemographic characteristics, health behaviours and medical history. They also underwent physical examination including height, weight and blood pressure measurement, and had blood and urine samples taken. Linked hospital inpatient records are available for most participants and primary care records are currently available for approximately half of participants. A subset of 157,366 out of 339,092 invited participants (46%) completed an online follow-up mental health questionnaire (MHO) between 2016-2017, covering 31% of all participants.

Exposures

Age at baseline assessment was the primary explanatory variable.

Lifetime depression was assessed as part of the MHQ using a modified version of the depression module of the Composite International Diagnostic Interview Short Form (CIDI-SF) and defined according to DSM-5 criteria for major depressive disorder (Supplementary Material 1) [107]. To achieve maximum coverage of the UK Biobank study, we also included in our definition or lifetime depression individuals who had reported during the nurse-led interview at baseline that a doctor had told them that they had depression (field 20002), participants who reported in response to a single-item question on the MHQ that a professional (doctors, nurse or person with specialist training such as psychologist or therapist) had diagnosed them with depression (field 20544), participants with a hospital inpatient record containing an ICD-10 code for depression (F32-F33; Supplementary Material 2), participants with a primary care record containing a Read v2 or CTV3 code for depression (see [108] for diagnostic codes and data extraction procedures), and those who were classified as individuals with probable depression according to Smith et al. [109] based on additional questions that were introduced during the later stages of the baseline assessment (Supplementary Material 3). We excluded individuals with any record of bipolar disorder or psychosis.

Healthy controls were defined as individuals who did not meet our criteria for lifetime depression and did not have a record of other mental disorders: (i) no "schizophrenia", "mania / bipolar disorder / manic depression", "anxiety / panic attacks", "obsessive compulsive disorder", "anorexia / bulimia / other eating disorder", "post-traumatic stress disorder" reported during the nurse-led interview at baseline (field 20002); (ii) no mental disorders reported in response to the single-item question on the MHQ (field 20544); (iii) no self-reported current psychotropic medication use at baseline (Supplementary Material 4) [100]; (iv) no linked hospital inpatient record that contained any ICD-10 Chapter V code except organic causes or substance use (F20-F99); (v) no primary care record containing a diagnostic code for mental disorders [108]: (vi) not classified as individual with probable bipolar disorder according to Smith et al. [109]; (vi) no Patient Health Questionnaire-9 (PHQ-9) sum score of \geq 5, which was assessed as part of the MHQ.

Outcomes

We examined 15 continuous physiological measures that were obtained at the baseline assessment, including maximal hand-grip strength, systolic and diastolic resting blood pressure, resting pulse rate, body mass index (BMI), waist-hip ratio, fat mass, fat-free mass, body fat percentage, peak expiratory flow, forced vital capacity (FVC), forced expiratory volume in one second (FEV₁), FVC/FEV₁ ratio, heel bone mineral density and arterial stiffness.

Physiological measures

All physiological measures were collected by certified healthcare technicians or nurses using a direct data entry system. Participants were asked to remove any outer garments, shoes, socks or tights. The assessment lasted about 10-15 minutes.

Hand-grip strength

Hand-grip strength in whole kilogram force units was measured using a Jamar J00105 hydraulic hand range dynamometer (measurement 0-90 kg). Participants were asked to sit upright in a chair and place their forearms on armrests. The dynamometer handle was set to the second incremental slot or, in participants with very large hands, moved to the third slot. Participants kept their elbow adjacent to their side and bent to a 90° angle with their thumb facing upward. A maximal score was obtained from each participant's right and left hand. We used the maximal grip strength of the participant's self-reported dominant hand. If no data on handedness were available, we used the highest value of both hands. This variable has been used previously in UK Biobank research [110], although other studies have used the highest value of left and right hand [111] or calculated the average grip strength from both hands [9]. We used absolute units because these are the simplest to use in risk assessment. A previous UK Biobank study found no evidence of differences in mortality or disease incidence prediction when grip strength was expressed in absolute terms compared to when expressed relative to anthropometric traits (height, weight, fat-free mass and BMI) [9].

Body composition

Weight measurements were obtained with a Tanita BC-418 MA body composition analyser, or, in individuals with pacemaker or females who reported that they were or might be pregnant, using a manual scale. Standing height was measured using a Seca 202 height measure. Body mass index (BMI) was calculated as weight divided by standing height squared (kg/m²). Waist and hip circumference in cm were measured using a Wessex non-stretchable sprung tape. Waist-to-hip ratio was calculated by dividing waist circumference by hip circumference. Whole body fat mass and fat-free mass in kg and body fat percentage (measurement range 1-75%) were estimated by electrical bio-impedance.

Pulmonary function

Volumetric measures of lung function were quantified using breath spirometry with a Vitalograph Pneumotrac 6800 following standard procedures. Participants were asked to record two to three blows, each lasting for at least six seconds, within a period of approximately six minutes. The reproducibility of the first two blows was automatically compared and, if acceptable (defined as a ≤5% difference in forced vital capacity (FVC) and forced expiratory volume in one second (FEV₁)), a third blow was not required. FVC in litres describes the maximum amount of air that can be exhaled when blowing out as fast as possible after a deep breath. FEV₁ in litres describes the amount of air that can be exhaled in one second when blowing out as fast as possible. We used the derived best measure for both FVC and FEV1 which was the maximum value from reproducible spirograms, in line with previous research [112]. Given that these measures are affected by several factors unrelated to pulmonary function (e.g., effort and body size), we also calculated the ratio of FEV_1 to FVC. Peak expiratory flow (PEF) in litres per minute represents a person's maximum speed of expiration. PEF is determined by physiological factors such as lung volume and elasticity or expiratory muscle strength. It is used for monitoring asthma and diagnosing chronic obstructive pulmonary disease. We calculated the average of all available readings. Spirometry was not performed in participants who confirmed or were unsure that they had any of the following contraindications: chest infection in the last month (i.e., influenza, bronchitis, severe cold or pneumonia); history of a detached retina; heart attack or surgery to eyes, chest or abdomen in the last three months; history of a collapsed lung; pregnancy in the 1st or 3rd trimester; currently on medication for tuberculosis.

Heel bone mineral density

Heel bone mineral density was estimated by quantitative ultrasound assessment of the calcaneus using a Sahara Clinical Bone Sonometer. Participants were asked to sit with their back straight and had their left heel measured first. Measurement of both heels was performed only during later stages of the baseline assessment. Measures of speed of sound in metres per second and broadband ultrasound attenuation (decibels/megahertz) were combined into a quantitative ultrasound index. From this an estimate of heel bone mineral density in grams per cm² was derived based on the assumption that sound waves travel differently through denser bones.

Cardiovascular measures

Blood pressure, pulse rate and arterial stiffness (pulse wave velocity) were measured by trained nurses during a separate stage of the baseline assessment.

Blood pressure

Seated systolic and diastolic resting blood pressure in millimetres of mercury (mmHg) was measured twice using an Omron 705 IT digital blood pressure monitor (measurement range 0-255 mmHg) following standard procedures. Participants were asked to loosen or remove any restrictive clothing and put their arm on a desktop. Measurements were taken from the left upper arm or, if impractical, from the right arm. If there was a problem with the measurement, it was repeated. Three different cuff sizes were available and a Seca tape was used to determine the circumference of the midpoint of the upper arm. If the largest cuff size was too small or the digital blood pressure monitor did not produce a reading, a manual sphygmomanometer was used in conjunction with a stethoscope. A second measurement was taken at least one minute after the first measure, following the same procedure. We used an average of the two readings to reduce potential measurement error.

Pulse rate

Resting pulse rate in beats per minute was recorded during the blood pressure measurements using the Omron 705 IT device or, exceptionally, a manual sphygmomanometer. We used an average of the two readings to reduce potential measurement error.

Arterial stiffness

Arterial stiffness (vascular reactivity) is an independent predictor of cardiovascular risk and mortality that can be measured rapidly, inexpensively, and without special

training [113]. Resting pulse wave velocity was measured non-invasively using finger photoplethysmography with a PulseTrace PCA2 infra-red sensor. The pulse waveform was recorded over a period of 10-15 seconds, with the sensor clipped to the end of the index finger of the nondominant hand while the participant was sitting. If the waveform did not fill at least 2/3 of the display of the device, or did not stabilize within one minute, the measurement was repeated on a larger finger or on the thumb. The shape of the waveform is directly related to the time it takes for the pulse wave to travel through the arterial tree in the lower body and to be reflected back to the finger. The time between the peaks of the waveform (the pulse wave peak-to-peak time, i.e., the difference between the peak values of direct and reflected components) was divided by the participant's height to obtain the arterial stiffness index in metres per second. A higher score on the index represents stiffer arteries. The method has been externally validated and is highly correlated with the gold-standard carotidfemoral pulse wave velocity [114].

Exclusion criteria

Participants for whom their genetic sex, inferred from the relative intensity of biological markers on the Y and X chromosomes, and self-reported sex did not match were excluded. Participants with missing data for any covariates or who responded "do not know" or "prefer not to answer" were excluded from all analyses.

Covariates

Covariates included ethnicity (White, Asian, Black, Chinese, Mixed-race or other), gross annual household income (<£18,000, £18,000–30,999, £31,000–51,999, £52,000–100,000 or >£100,000), physical activity (number of days per week spent walking, engaging in moderate-intensity physical activity and engaging in vigorous-intensity physical activity for ≥ 10 minutes continuously), smoking status (never, former or current), alcohol intake frequency (never, special occasions only, one to three times a month, once or twice a week, three or four times a week or daily or almost daily), sleep duration (hours per day) and, for cardiovascular measures, current use of antihypertensive medications at baseline (yes/no). See our previous publication [105] for further details on these variables.

Statistical analyses

All analyses, except the sensitivity analyses, were prespecified prior to inspection of the data (preregistration: osf.io/pc76g) and algorithms were tested on simulated data. Statistical analyses were conducted using R (version 3.6.0). Sample characteristics were summarised using means and standard deviations or counts and percentages. We also present the number of individuals who met our criteria for lifetime depression and healthy control. Kernel density plots of all physiological measures stratified by lifetime depression case status are presented separately for males and females. Differences between the sexes and between cases and controls were estimated using standardised mean differences (\pm 95% confidence intervals).

We examined the relationship between each physiological measure and age using generalised additive models (GAMs) with the 'mgcv' package in R [115]. Each measure was modelled against a penalised regression spline function of age with separate smooths for individuals with lifetime depression and healthy controls. GAMs are flexible modelling approaches that allow for the relationship between an outcome variable and a continuous exposure to be represented by a non-linear smooth curve while controlling for covariates. They are particularly useful if a linear model does not capture key aspects of the relationship between variables and attempt to achieve maximum goodness-of-fit while maintaining parsimony of the fitted curve to minimize overfitting. Smoothing parameters were selected using the restricted maximum likelihood method and we used the default option of ten basis functions to represent smooth terms in each model.

Two models were fit for males and females separately:

- Unadjusted model: physiological measure ~ lifetime depression + s(age, by lifetime depression).
- Adjusted model: physiological measure ~ lifetime depression + s(age, by lifetime depression) + covariates (ethnicity, household income, physical activity, smoking status, alcohol intake frequency and sleep duration).

where s(age, by lifetime depression) represents the smooth function for age, stratified by lifetime depression status. For cardiovascular measures, the adjusted model additionally included self-reported antihypertensive medication use.

To formally test whether the relationship between physiological measures and age differed between individuals with lifetime depression and healthy controls, we also fit, in separate analyses, models that included a reference smooth for healthy controls and a difference smooth for individuals with lifetime depression compared to healthy controls. For these analyses, lifetime depression status was coded as an ordered factor in R. If the difference smooth differs from zero, individuals with lifetime depression and healthy controls follow a different trend with age.

Adjusted *p*-values were calculated using the p.adjust() command in R to account for multiple testing across each set of analyses of the 15 physiological measures. Two methods were used: (1) Bonferroni and (2) Benjamini and Hochberg [116], all two-tailed, with α = .05 and false discovery rate of 5%, respectively.

To address potential concerns about the validity and reliability of our case definition, we conducted sensitivity analyses in which we restricted the samples to (i) individuals with lifetime depression according to at least two different data sources and (ii) individuals with lifetime depression status assessed using the CIDI-SF. These sensitivity analyses were not preregistered.

Ethics

Ethical approval for the UK Biobank study has been granted by the National Information Governance Board for Health and Social Care and the NHS North West Multicentre Research Ethics Committee (11/NW/0382). No project-specific ethical approval is needed. Data access permission has been granted under UK Biobank application 45514.

Data sharing statement

The data used are available to all bona fide researchers for health-related research that is in the public interest, subject to an application process and approval criteria. Study materials are publicly available online at http://www.ukbiobank.ac.uk.

AUTHOR CONTRIBUTIONS

CML acquired the studentship funding, interpreted the findings and critically reviewed the manuscript. JM conceived the idea of the study, acquired the data, carried out the statistical analysis, interpreted the findings, wrote the manuscript and revised the manuscript for final submission. Both authors read and approved the final manuscript. JM had full access to all data used in this study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

ACKNOWLEDGMENTS

This research has been conducted using data from UK Biobank, a major biomedical database. This project made use of time on Rosalind HPC, funded by Guy's and St Thomas' Hospital NHS Trust Biomedical Research Centre (GSTT-BRC), South London and Maudsley NHS Trust Biomedical Research Centre (SLAM-BRC), and Faculty of Natural Mathematics and Science (NMS) at King's College London.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest. CML is a member of the Scientific Advisory Board of Myriad Neuroscience.

FUNDING

JM receives studentship funding from the Biotechnology and Biological Sciences Research Council (BBSRC) (ref: 2050702) and Eli Lilly and Company Limited. CML is part-funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

REFERENCES

- Plana-Ripoll O, Weye N, Momen NC, Christensen MK, Iburg KM, Laursen TM, McGrath JJ. Changes over time in the differential mortality gap in individuals with mental disorders. JAMA Psychiatry. 2020; 77:648–50. <u>https://doi.org/10.1001/jamapsychiatry.2020.0334</u> PMID:<u>32267492</u>
- Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS, and National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289:3095–105. <u>https://doi.org/10.1001/jama.289.23.3095</u> PMID:<u>12813115</u>
- Daskalopoulou C, Koukounari A, Wu YT, Terrera GM, Caballero FF, de la Fuente J, Tyrovolas S, Panagiotakos DB, Prince M, Prina M. Healthy ageing trajectories and lifestyle behaviour: the Mexican Health and Aging Study. Sci Rep. 2019; 9:11041. <u>https://doi.org/10.1038/s41598-019-47238-w</u> PMID:31363117
- Wilkinson P, Ruane C, Tempest K. Depression in older adults. BMJ. 2018; 363:k4922. <u>https://doi.org/10.1136/bmj.k4922</u> PMID:<u>30487197</u>
- López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153:1194–217.

https://doi.org/10.1016/j.cell.2013.05.039 PMID:23746838

- Cole JH, Franke K. Predicting age using neuroimaging: innovative brain ageing biomarkers. Trends Neurosci. 2017; 40:681–90. <u>https://doi.org/10.1016/j.tins.2017.10.001</u> PMID:29074032
- Veronese N, Stubbs B, Fontana L, Trevisan C, Bolzetta F, Rui M, Sartori L, Musacchio E, Zambon S, Maggi S, Perissinotto E, Corti MC, Crepaldi G, et al. A comparison of objective physical performance tests and future mortality in the elderly people. J Gerontol A Biol Sci Med Sci. 2017; 72:362–68. <u>https://doi.org/10.1093/gerona/glw139</u>

PMID:27470299

- Celis-Morales CA, Welsh P, Lyall DM, Steell L, Petermann F, Anderson J, Iliodromiti S, Sillars A, Graham N, Mackay DF, Pell JP, Gill JM, Sattar N, Gray SR. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ. 2018; 361:k1651. <u>https://doi.org/10.1136/bmj.k1651</u> PMID:29739772
- Ho FK, Celis-Morales CA, Petermann-Rocha F, Sillars A, Welsh P, Welsh C, Anderson J, Lyall DM, Mackay DF, Sattar N, Gill JM, Pell JP, Gray SR. The association of grip strength with health outcomes does not differ if grip strength is used in absolute or relative terms: a prospective cohort study. Age Ageing. 2019; 48: 684–91.

https://doi.org/10.1093/ageing/afz068 PMID:<u>31204772</u>

- Dodds RM, Syddall HE, Cooper R, Benzeval M, Deary IJ, Dennison EM, Der G, Gale CR, Inskip HM, Jagger C, Kirkwood TB, Lawlor DA, Robinson SM, et al. Grip strength across the life course: normative data from twelve British studies. PLoS One. 2014; 9:e113637. <u>https://doi.org/10.1371/journal.pone.0113637</u> PMID:25474696
- 11. Cheng S, Xanthakis V, Sullivan LM, Vasan RS. Blood pressure tracking over the adult life course: patterns and correlates in the Framingham heart study. Hypertension. 2012; 60:1393–99. <u>https://doi.org/10.1161/HYPERTENSIONAHA.112.2017</u> <u>80</u> PMID:23108660
- Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN, Cheng S. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020; 5:19–26.

https://doi.org/10.1001/jamacardio.2019.5306 PMID:31940010

- Wolkowitz OM. Accelerated biological aging in serious mental disorders. World Psychiatry. 2018; 17:144–45. <u>https://doi.org/10.1002/wps.20546</u> PMID:<u>29856570</u>
- Austad SN, Bartke A. Sex differences in longevity and in responses to anti-aging interventions: a mini-review. Gerontology. 2015; 62:40–46. <u>https://doi.org/10.1159/000381472</u> PMID:<u>25968226</u>
- McCarthy MM, Nugent BM, Lenz KM. Neuroimmunology and neuroepigenetics in the establishment of sex differences in the brain. Nat Rev Neurosci. 2017; 18:471–84. <u>https://doi.org/10.1038/nrn.2017.61</u> PMID:<u>28638119</u>
- Mutz J, Young AH, Lewis CM. Age-related changes in physiology in individuals with bipolar disorder. medRxiv. 2021. <u>https://doi.org/10.1101/2021.03.05.21252987</u>
- Cooper R, Hardy R, Aihie Sayer A, Ben-Shlomo Y, Birnie K, Cooper C, Craig L, Deary IJ, Demakakos P, Gallacher J, McNeill G, Martin RM, Starr JM, et al, and HALCyon study team. Age and gender differences in physical capability levels from mid-life onwards: the harmonisation and meta-analysis of data from eight UK cohort studies. PLoS One. 2011; 6:e27899. https://doi.org/10.1371/journal.pone.0027899 PMID:22114723
- Keevil VL, Hayat S, Dalzell N, Moore S, Bhaniani A, Luben R, Wareham NJ, Khaw KT. The physical capability of community-based men and women from a British cohort: the European Prospective Investigation into Cancer (EPIC)-Norfolk study. BMC Geriatr. 2013; 13:93. <u>https://doi.org/10.1186/1471-2318-13-93</u> PMID:24020915
- 19. Beller J, Miething A, Regidor E, Lostao L, Epping J, Geyer S. Trends in grip strength: age, period, and cohort effects on grip strength in older adults from Germany, Sweden, and Spain. SSM Popul Health. 2019; 9:100456.

https://doi.org/10.1016/j.ssmph.2019.100456 PMID:<u>31453311</u>

- Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995; 25:305–13. <u>https://doi.org/10.1161/01.hyp.25.3.305</u> PMID:<u>7875754</u>
- 21. AlGhatrif M, Strait JB, Morrell CH, Canepa M, Wright J, Elango P, Scuteri A, Najjar SS, Ferrucci L, Lakatta EG.

Longitudinal trajectories of arterial stiffness and the role of blood pressure: the Baltimore Longitudinal Study of Aging. Hypertension. 2013; 62:934–41. https://doi.org/10.1161/HYPERTENSIONAHA.113.0144 <u>5</u> PMID:24001897

- Quer G, Gouda P, Galarnyk M, Topol EJ, Steinhubl SR. Inter- and intraindividual variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time of year: Retrospective, longitudinal cohort study of 92,457 adults. PLoS One. 2020; 15:e0227709. https://doi.org/10.1371/journal.pone.0227709 PMID:32023264
- Liao SY, Lin X, Christiani DC. Occupational exposures and longitudinal lung function decline. Am J Ind Med. 2015; 58:14–20. <u>https://doi.org/10.1002/ajim.22389</u> PMID:25384732
- 24. Nunn AJ, Gregg I. New regression equations for predicting peak expiratory flow in adults. BMJ. 1989; 298:1068–70. <u>https://doi.org/10.1136/bmj.298.6680.1068</u> PMID:2497892
- van Oostrom SH, Engelfriet PM, Verschuren WM, Schipper M, Wouters IM, Boezen M, Smit HA, Kerstjens HA, Picavet HS. Aging-related trajectories of lung function in the general population-The Doetinchem Cohort Study. PLoS One. 2018; 13:e0197250. <u>https://doi.org/10.1371/journal.pone.0197250</u> PMID:<u>29768509</u>
- Li C, Ford ES, Zhao G, Balluz LS, Giles WH. Estimates of body composition with dual-energy X-ray absorptiometry in adults. Am J Clin Nutr. 2009; 90:1457–65. https://doi.org/10.3945/ajcn.2009.28141

PMID:19812179

- 27. He X, Li Z, Tang X, Zhang L, Wang L, He Y, Jin T, Yuan D. Age- and sex-related differences in body composition in healthy subjects aged 18 to 82 years. Medicine. 2018; 97:e11152. <u>https://doi.org/10.1097/MD.000000000011152</u> PMID:29924020
- 28. Frenzel A, Binder H, Walter N, Wirkner K, Loeffler M, Loeffler-Wirth H. The aging human body shape. NPJ Aging Mech Dis. 2020; 6:5. <u>https://doi.org/10.1038/s41514-020-0043-9</u> PMID:32218988
- Larsson I, Lissner L, Samuelson G, Fors H, Lantz H, Näslund I, Carlsson LM, Sjöström L, Bosaeus I. Body composition through adult life: Swedish reference data on body composition. Eur J Clin Nutr. 2015; 69:837–42. <u>https://doi.org/10.1038/ejcn.2014.268</u> PMID:<u>25514897</u>

 Malkin I, Bigman G, Matias R, Kalichman L, Seibel M, Kobyliansky E, Livshits G. Age-related changes of bone strength phenotypes: observational follow-up study of hand bone mineral density. Archives of Osteoporosis. 2006; 1:59–68.

https://doi.org/10.1007/s11657-006-0009-y

- 31. Ross RD, Shah RC, Leurgans SE, Buchman AS, Bennett DA. Association of heel bone mineral density with incident disability and mortality in community-dwelling older adults. JBMR Plus. 2020; 4:e10390. <u>https://doi.org/10.1002/jbm4.10390</u>
 - PMID:32995693
- 32. Merz AA, Cheng S. Sex differences in cardiovascular ageing. Heart. 2016; 102:825–31. <u>https://doi.org/10.1136/heartjnl-2015-308769</u> PMID:<u>26917537</u>
- Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension. 2009; 54:1328–36. <u>https://doi.org/10.1161/HYPERTENSIONAHA.109.1376</u> 53 PMID:19884567
- 34. Mitchell GF, Parise H, Benjamin EJ, Larson MG, Keyes MJ, Vita JA, Vasan RS, Levy D. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004; 43:1239–45. <u>https://doi.org/10.1161/01.HYP.0000128420.01881.aa</u> PMID:15123572
- Russo C, Jin Z, Palmieri V, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Arterial stiffness and wave reflection: sex differences and relationship with left ventricular diastolic function. Hypertension. 2012; 60:362–68. https://doi.org/10.1161/HYPERTENSIONAHA.112.1911

<u>48</u> PMID:<u>22753223</u>
36. Coutinho T, Borlaug BA, Pellikka PA, Turner ST, Kullo IJ.

Sex differences in arterial stiffness and ventriculararterial interactions. J Am Coll Cardiol. 2013; 61:96–103. https://doi.org/10.1016/j.jacc.2012.08.997

https://doi.org/10.1016/j.jacc.2012.08.9 PMID:<u>23122799</u>

 Franklin SS, Gustin W 4t, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997; 96: 308–15.

https://doi.org/10.1161/01.cir.96.1.308 PMID:<u>9236450</u>

38. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodríguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003; 289:2363–69.

https://doi.org/10.1001/jama.289.18.2363 PMID:<u>12746359</u>

- 39. Kyle UG, Genton L, Slosman DO, Pichard C. Fat-free and fat mass percentiles in 5225 healthy subjects aged 15 to 98 years. Nutrition. 2001; 17:534–41. <u>https://doi.org/10.1016/s0899-9007(01)00555-x</u> PMID:<u>11448570</u>
- Jackson AS, Janssen I, Sui X, Church TS, Blair SN. Longitudinal changes in body composition associated with healthy ageing: men, aged 20-96 years. Br J Nutr. 2012; 107:1085–91. <u>https://doi.org/10.1017/S0007114511003886</u>

PMID:21810289
41. Thomas ET, Guppy M, Straus SE, Bell KJ, Glasziou P. Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies. BMJ

Open. 2019; 9:e028150. https://doi.org/10.1136/bmjopen-2018-028150 PMID:31248928

- 42. Malkin I, Karasik D, Livshits G, Kobyliansky E. Modelling of age-related bone loss using cross-sectional data. Ann Hum Biol. 2002; 29:256–70. <u>https://doi.org/10.1080/03014460110075729</u> PMID:<u>12031136</u>
- 43. Qian X, Su C, Zhang B, Qin G, Wang H, Wu Z. Changes in distributions of waist circumference, waist-to-hip ratio and waist-to-height ratio over an 18-year period among Chinese adults: a longitudinal study using quantile regression. BMC Public Health. 2019; 19:700.

https://doi.org/10.1186/s12889-019-6927-6 PMID:<u>31170949</u>

- 44. McDowell CP, Gordon BR, Herring MP. Sex-related differences in the association between grip strength and depression: results from the Irish Longitudinal Study on Ageing. Exp Gerontol. 2018; 104:147–52. <u>https://doi.org/10.1016/j.exger.2018.02.010</u> PMID:<u>29454029</u>
- 45. Ashdown-Franks G, Stubbs B, Koyanagi A, Schuch F, Firth J, Veronese N, Vancampfort D. Handgrip strength and depression among 34,129 adults aged 50 years and older in six low- and middle-income countries. J Affect Disord. 2019; 243:448–54. <u>https://doi.org/10.1016/j.jad.2018.09.036</u> PMID:30273883
- 46. Han KM, Chang J, Yoon HK, Ko YH, Ham BJ, Kim YK, Han C. Relationships between hand-grip strength, socioeconomic status, and depressive symptoms in

community-dwelling older adults. J Affect Disord. 2019; 252:263–70. https://doi.org/10.1016/j.jad.2019.04.023 PMID:30991254

- 47. Volaklis K, Mamadjanov T, Meisinger C, Linseisen J. Association between muscular strength and depressive symptoms : a narrative review. Wien Klin Wochenschr. 2019; 131:255–64. <u>https://doi.org/10.1007/s00508-019-1491-8</u> PMID:30963333
- 48. Veronese N, Stubbs B, Trevisan C, Bolzetta F, De Rui M, Solmi M, Sartori L, Musacchio E, Zambon S, Perissinotto E, Baggio G, Crepaldi G, Manzato E, et al. Poor physical performance predicts future onset of depression in elderly people: Progetto Veneto Anziani Longitudinal Study. Phys Ther. 2017; 97:659–68. <u>https://doi.org/10.1093/ptj/pzx017</u> PMID:<u>28201628</u>
- 49. Smith L, White S, Stubbs B, Hu L, Veronese N, Vancampfort D, Hamer M, Gardner B, Yang L. Depressive symptoms, handgrip strength, and weight status in US older adults. J Affect Disord. 2018; 238:305–10. <u>https://doi.org/10.1016/j.jad.2018.06.016</u>

PMID:<u>29902734</u>

- 50. Suija K, Timonen M, Suviola M, Jokelainen J, Järvelin MR, Tammelin T. The association between physical fitness and depressive symptoms among young adults: results of the Northern Finland 1966 birth cohort study. BMC Public Health. 2013; 13:535. <u>https://doi.org/10.1186/1471-2458-13-535</u> PMID:<u>23731782</u>
- Hildrum B, Mykletun A, Holmen J, Dahl AA. Effect of anxiety and depression on blood pressure: 11-year longitudinal population study. Br J Psychiatry. 2008; 193:108–13.

https://doi.org/10.1192/bjp.bp.107.045013 PMID:<u>18669991</u>

- 52. Hildrum B, Mykletun A, Stordal E, Bjelland I, Dahl AA, Holmen J. Association of low blood pressure with anxiety and depression: the Nord-Trøndelag Health Study. J Epidemiol Community Health. 2007; 61:53–58. <u>https://doi.org/10.1136/jech.2005.044966</u> PMID:17183016
- 53. Tikhonoff V, Hardy R, Deanfield J, Friberg P, Kuh D, Muniz G, Pariante CM, Hotopf M, Richards M, and NSHD scientific and data collection teams. Symptoms of anxiety and depression across adulthood and blood pressure in late middle age: the 1946 British birth cohort. J Hypertens. 2014; 32:1590–98. <u>https://doi.org/10.1097/HJH.00000000000244</u> PMID:24906173

- Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, van Dyck R, Penninx BW. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension. 2009; 53:631–38. <u>https://doi.org/10.1161/HYPERTENSIONAHA.108.1266</u> 98 PMID:19237679
- 55. Shinn EH, Poston WS, Kimball KT, St Jeor ST, Foreyt JP. Blood pressure and symptoms of depression and anxiety: a prospective study. Am J Hypertens. 2001; 14:660–64. <u>https://doi.org/10.1016/s0895-7061(01)01304-8</u> PMID:11482304
- 56. Meng L, Chen D, Yang Y, Zheng Y, Hui R. Depression increases the risk of hypertension incidence: a metaanalysis of prospective cohort studies. J Hypertens. 2012; 30:842–51. <u>https://doi.org/10.1097/HJH.0b013e32835080b7</u> PMID:22343537
- 57. Paterniti S, Verdier-Taillefer MH, Geneste C, Bisserbe JC, Alpérovitch A. Low blood pressure and risk of depression in the elderly. A prospective community-based study. Br J Psychiatry. 2000; 176:464–67. <u>https://doi.org/10.1192/bjp.176.5.464</u> PMID:<u>10912223</u>
- 58. Gould CE, Beaudreau SA. Association between depression and anxiety on blood pressure dysregulation and pulse in the Health and Retirement Study. Int J Geriatr Psychiatry. 2013; 28:1045–53. <u>https://doi.org/10.1002/gps.3926</u> PMID:<u>23335009</u>
- Lechin F, van der Dijs B, Orozco B, Lechin ME, Báez S, Lechin AE, Rada I, Acosta E, Arocha L, Jiménez V. Plasma neurotransmitters, blood pressure, and heart rate during supine-resting, orthostasis, and moderate exercise conditions in major depressed patients. Biol Psychiatry. 1995; 38:166–73.

https://doi.org/10.1016/0006-3223(94)00258-5 PMID:<u>7578659</u>

- Kemp AH, Quintana DS, Quinn CR, Hopkinson P, Harris AW. Major depressive disorder with melancholia displays robust alterations in resting state heart rate and its variability: implications for future morbidity and mortality. Front Psychol. 2014; 5:1387. <u>https://doi.org/10.3389/fpsyg.2014.01387</u> PMID:25505893
- Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010; 67:220–29.

https://doi.org/10.1001/archgenpsychiatry.2010.2 PMID:20194822

- Geoffroy MC, Li L, Power C. Depressive symptoms and body mass index: co-morbidity and direction of association in a British birth cohort followed over 50 years. Psychol Med. 2014; 44:2641–52. <u>https://doi.org/10.1017/S0033291714000142</u> PMID:<u>25055177</u>
- Rivenes AC, Harvey SB, Mykletun A. The relationship between abdominal fat, obesity, and common mental disorders: results from the HUNT study. J Psychosom Res. 2009; 66:269–75. <u>https://doi.org/10.1016/j.jpsychores.2008.07.012</u> PMID:19302883
- 64. Ho RC, Niti M, Kua EH, Ng TP. Body mass index, waist circumference, waist-hip ratio and depressive symptoms in Chinese elderly: a population-based study. Int J Geriatr Psychiatry. 2008; 23:401–08. https://doi.org/10.1002/gps.1893
 PMID:<u>17879255</u>
- Zhi T, Wang Q, Liu Z, Zhu Y, Wang Y, Shi R, Wang Z, Chu X, Wang X, Jiang X. Body mass index, waist circumference and waist-hip ratio are associated with depressive symptoms in older Chinese women: results from the Rugao Longevity and Ageing Study (RuLAS). Aging Ment Health. 2017; 21:518–23. https://doi.org/10.1080/13607863.2015.1124837 PMID:26689763
- 66. de Wit LM, van Straten A, van Herten M, Penninx BW, Cuijpers P. Depression and body mass index, a ushaped association. BMC Public Health. 2009; 9:14. <u>https://doi.org/10.1186/1471-2458-9-14</u> PMID:<u>19144098</u>
- 67. Gale CR, Sayer AA, Cooper C, Dennison EM, Starr JM, Whalley LJ, Gallacher JE, Ben-Shlomo Y, Kuh D, Hardy R, Craig L, Deary IJ, and HALCyon Study Team. Factors associated with symptoms of anxiety and depression in five cohorts of community-based older people: the HALCyon (Healthy Ageing across the Life Course) Programme. Psychol Med. 2011; 41:2057–73. <u>https://doi.org/10.1017/S0033291711000195</u> PMID:<u>21349224</u>
- Speed MS, Jefsen OH, Børglum AD, Speed D, Østergaard SD. Investigating the association between body fat and depression via Mendelian randomization. Transl Psychiatry. 2019; 9:184. <u>https://doi.org/10.1038/s41398-019-0516-4</u> PMID:<u>31383844</u>
- 69. Baldofski S, Mauche N, Dogan-Sander E, Bot M, Brouwer IA, Paans NP, Cabout M, Gili M, van Grootheest G, Hegerl U, Owens M, Roca M, Visser M, et al. Depressive symptom clusters in relation to body

weight status: results from two large european multicenter studies. Front Psychiatry. 2019; 10:858. https://doi.org/10.3389/fpsyt.2019.00858 PMID:31824355

- 70. UI-Haq Z, Smith DJ, Nicholl BI, Cullen B, Martin D, Gill JM, Evans J, Roberts B, Deary IJ, Gallacher J, Hotopf M, Craddock N, Mackay DF, Pell JP. Gender differences in the association between adiposity and probable major depression: a cross-sectional study of 140,564 UK Biobank participants. BMC Psychiatry. 2014; 14:153. <u>https://doi.org/10.1186/1471-244X-14-153</u> PMID:<u>24884621</u>
- 71. Wiltink J, Michal M, Wild PS, Zwiener I, Blettner M, Münzel T, Schulz A, Kirschner Y, Beutel ME. Associations between depression and different measures of obesity (BMI, WC, WHtR, WHR). BMC Psychiatry. 2013; 13:223. <u>https://doi.org/10.1186/1471-244X-13-223</u> PMID:24028572
- Mezuk B, Golden SH, Eaton WW, Lee HB. Depression and body composition among older adults. Aging Ment Health. 2012; 16:167–72. <u>https://doi.org/10.1080/13607863.2011.583631</u>
 PMID:21702709
- 73. Giovannini S, Macchi C, Liperoti R, Laudisio A, Coraci D, Loreti C, Vannetti F, Onder G, Padua L, and Mugello Study Working Group. Association of body fat with health-related quality of life and depression in nonagenarians: the Mugello Study. J Am Med Dir Assoc. 2019; 20:564–68. <u>https://doi.org/10.1016/j.jamda.2019.01.128</u> PMID:30852165
- 74. van Milligen BA, Lamers F, de Hoop GT, Smit JH, Penninx BW. Objective physical functioning in patients with depressive and/or anxiety disorders. J Affect Disord. 2011; 131:193–99. <u>https://doi.org/10.1016/j.jad.2010.12.005</u> PMID:21195484
- 75. Spitzer C, Gläser S, Grabe HJ, Ewert R, Barnow S, Felix SB, Freyberger HJ, Völzke H, Koch B, Schäper C. Mental health problems, obstructive lung disease and lung function: findings from the general population. J Psychosom Res. 2011; 71:174–79. https://doi.org/10.1016/j.jpsychores.2011.03.005 PMID:21843753
- 76. Park Y, Jung JY, Kim YS, Chung KS, Song JH, Kim SY, Kim EY, Kang YA, Park MS, Chang J, Leem AY. Relationship between depression and lung function in the general population in Korea: a retrospective cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2018; 13: 2207–13.

https://doi.org/10.2147/COPD.S169025 PMID:30140153

- 77. Giltay EJ, Nissinen A, Giampaoli S, Zitman FG, Kromhout D. Low respiratory function increases the risk of depressive symptoms in later life in men. Psychosom Med. 2010; 72:53–60. <u>https://doi.org/10.1097/PSY.0b013e3181c2ca39</u> PMID:<u>19933509</u>
- 78. Rosenblat JD, Gregory JM, Carvalho AF, McIntyre RS. Depression and disturbed bone metabolism: a narrative review of the epidemiological findings and postulated mechanisms. Curr Mol Med. 2016; 16: 165–78. <u>https://doi.org/10.2174/156652401666616012614430</u> 3 PMID:26812918
- 79. Wu Q, Magnus JH, Liu J, Bencaz AF, Hentz JG. Depression and low bone mineral density: a metaanalysis of epidemiologic studies. Osteoporos Int. 2009; 20:1309–20. <u>https://doi.org/10.1007/s00198-009-0918-x</u> PMID:<u>19343469</u>
- Williams LJ, Pasco JA, Jacka FN, Hodge JM, Kotowicz MA, Berk M. Quantitative Heel Ultrasound (QUS) measures of bone quality in association with mood and anxiety disorders. J Affect Disord. 2013; 146:395–400. <u>https://doi.org/10.1016/j.jad.2012.09.025</u> PMID:<u>23122528</u>
- Atteritano M, Lasco A, Mazzaferro S, Macrì I, Catalano A, Santangelo A, Bagnato G, Bagnato G, Frisina N. Bone mineral density, quantitative ultrasound parameters and bone metabolism in postmenopausal women with depression. Intern Emerg Med. 2013; 8:485–91.

https://doi.org/10.1007/s11739-011-0628-1 PMID:21584846

- Peng L, Bi S, Liu X, Long T, Zhao Y, Li F, Yang T, Zhang C. Association between depressive symptoms and arterial stiffness: a cross-sectional study in the general Chinese population. BMJ Open. 2020; 10:e033408. <u>https://doi.org/10.1136/bmjopen-2019-033408</u>
 PMID:<u>32114467</u>
- Seldenrijk A, van Hout HP, van Marwijk HW, de Groot E, Gort J, Rustemeijer C, Diamant M, Penninx BW. Depression, anxiety, and arterial stiffness. Biol Psychiatry. 2011; 69:795–803. <u>https://doi.org/10.1016/j.biopsych.2010.12.034</u> PMID:<u>21334599</u>
- 84. Dregan A, Rayner L, Davis KA, Bakolis I, Arias de la Torre J, Das-Munshi J, Hatch SL, Stewart R, Hotopf M. Associations between depression, arterial stiffness, and metabolic syndrome among adults in the UK Biobank population study: a mediation analysis. JAMA Psychiatry. 2020; 77:598–606.

https://doi.org/10.1001/jamapsychiatry.2019.4712 PMID:<u>31995135</u>

- Lever-van Milligen BA, Lamers F, Smit JH, Penninx BW. Six-year trajectory of objective physical function in persons with depressive and anxiety disorders. Depress Anxiety. 2017; 34:188–97. <u>https://doi.org/10.1002/da.22557</u> PMID:<u>27701790</u>
- 86. Shah MT, Zonderman AB, Waldstein SR. Sex and age differences in the relation of depressive symptoms with blood pressure. Am J Hypertens. 2013; 26:1413–20. <u>https://doi.org/10.1093/ajh/hpt135</u> PMID:23959543
- Erez HB, Weller A, Vaisman N, Kreitler S. The relationship of depression, anxiety and stress with low bone mineral density in post-menopausal women. Arch Osteoporos. 2012; 7:247–55. <u>https://doi.org/10.1007/s11657-012-0105-0</u> PMID:<u>23095987</u>
- 88. Yirmiya R, Bab I. Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry. 2009; 66:423–32. <u>https://doi.org/10.1016/j.biopsych.2009.03.016</u> PMID:<u>19446797</u>
- 89. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Cauley JA, Whooley MA, Ensrud KE, and Study of Osteoporotic Fractures. Depressive symptoms and rates of bone loss at the hip in older women. J Am Geriatr Soc. 2007; 55:824–31. <u>https://doi.org/10.1111/j.1532-5415.2007.01194.x</u> PMID:17537081
- 90. Diem SJ, Harrison SL, Haney E, Cauley JA, Stone KL, Orwoll E, Ensrud KE, and Osteoporotic Fractures in Men (MrOS) Research Group. Depressive symptoms and rates of bone loss at the hip in older men. Osteoporos Int. 2013; 24:111–19. <u>https://doi.org/10.1007/s00198-012-1975-0</u> PMID:22461074
- 91. Cizza G, Mistry S, Nguyen VT, Eskandari F, Martinez P, Torvik S, Reynolds JC, Gold PW, Sinaii N, Csako G, and POWER Study Group. Do premenopausal women with major depression have low bone mineral density? A 36-month prospective study. PLoS One. 2012; 7:e40894.

https://doi.org/10.1371/journal.pone.0040894 PMID:22848407

92. Mezuk B, Eaton WW, Golden SH, Wand G, Lee HB. Depression, antidepressants, and bone mineral density in a population-based cohort. J Gerontol A Biol Sci Med Sci. 2008; 63:1410–15.

https://doi.org/10.1093/gerona/63.12.1410 PMID:<u>19126857</u>

93. Pinto E. Blood pressure and ageing. Postgrad Med J. 2007; 83:109–14.

https://doi.org/10.1136/pgmj.2006.048371 PMID:<u>17308214</u>

- 94. Hübel C, Gaspar HA, Coleman JR, Hanscombe KB, Purves K, Prokopenko I, Graff M, Ngwa JS, Workalemahu T, O'Reilly PF, Bulik CM, Breen G, ADHD Working Group of the Psychiatric Genomics Consortium, Meta-Analyses of Glucose and Insulinrelated traits consortium (MAGIC), Autism Working Group of the Psychiatric Genomics Consortium, Bipolar Disorder Working Group of the Psychiatric Genomics Consortium, Eating Disorders Working Group of the Psychiatric Genomics Consortium, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, OCD and Tourette Syndrome Working Group of the Psychiatric Genomics Consortium, PTSD Working Group of the Psychiatric Genomics Consortium, Schizophrenia Working Group of the Psychiatric Genomics Consortium, Sex Differences Cross Disorder Working Group of the Psychiatric Genomics Consortium, Substance Use Disorders Working Group of the Psychiatric Genomics Consortium, German Borderline Genomics Consortium, and International Headache Genetics Consortium. Genetic correlations of psychiatric traits with body composition and glycemic traits are sex- and age-dependent. Nat Commun. 2019; 10:5765. https://doi.org/10.1038/s41467-019-13544-0 PMID:31852892
- 95. Bäckman K, Joas E, Falk H, Mitnitski A, Rockwood K, Skoog I. Changes in the lethality of frailty over 30 years: evidence from two cohorts of 70-year-olds in Gothenburg Sweden. J Gerontol A Biol Sci Med Sci. 2017; 72:945–50. https://doi.org/10.1093/gerona/glw160 PMID:27522060
- 96. Yu R, Wong M, Chong KC, Chang B, Lum CM, Auyeung TW, Lee J, Lee R, Woo J. Trajectories of frailty among Chinese older people in Hong Kong between 2001 and 2012: an age-period-cohort analysis. Age Ageing. 2018; 47:254–61. https://doi.org/10.1093/ageing/afx170 PMID:29161361
- 97. Yang Y, Lee LC. Dynamics and heterogeneity in the process of human frailty and aging: evidence from the U.S. older adult population. J Gerontol B Psychol Sci Soc Sci. 2010; 65:246–55. https://doi.org/10.1093/geronb/gbp102 PMID:20007299
- 98. Glanville KP, Coleman JR, Howard DM, Pain O, Hanscombe KB, Jermy B, Arathimos R, Hübel C, Breen G, O'Reilly PF, Lewis CM. Multiple measures of depression to enhance validity of major depressive disorder in the UK Biobank. BJPsych Open. 2021; 7:e44.

https://doi.org/10.1192/bjo.2020.145 PMID:33541459

99. Davis K, Hotopf M. Mental health phenotyping in UK Biobank. Progress in Neurology and Psychiatry. 2019; 23:4–7.

https://doi.org/10.1002/pnp.522

- 100. Davis KA, Cullen B, Adams M, Brailean A, Breen G, Coleman JR, Dregan A, Gaspar HA, Hübel C, Lee W, McIntosh AM, Nolan J, Pearsall R, Hotopf M. Indicators of mental disorders in UK Biobank-A comparison of approaches. Int J Methods Psychiatr Res. 2019; 28:e1796. <u>https://doi.org/10.1002/mpr.1796</u> PMID:<u>31397039</u>
- 101. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, Collins R, Allen NE. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol. 2017; 186:1026–34. https://doi.org/10.1093/aje/kwx246 PMID:28641372
- 102. Batty GD, Gale CR, Kivimäki M, Deary IJ, Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. BMJ. 2020; 368:m131.

https://doi.org/10.1136/bmj.m131 PMID:<u>32051121</u>

- 103. Knudsen AK, Hotopf M, Skogen JC, Overland S, Mykletun A. The health status of nonparticipants in a population-based health study: the Hordaland Health Study. Am J Epidemiol. 2010; 172:1306–14. <u>https://doi.org/10.1093/aje/kwq257</u> PMID:<u>20843863</u>
- 104. Ansai JH, Rebelatto JR. Effect of two physical exercise protocols on cognition and depressive symptoms in oldest-old people: a randomized controlled trial. Geriatr Gerontol Int. 2015; 15:1127–34. https://doi.org/10.1111/ggi.12411
 PMID:25407380
- 105. Mutz J, Roscoe CJ, Lewis CM. Exploring health in the UK Biobank: associations with sociodemographic characteristics, psychosocial factors, lifestyle and environmental exposures. medRxiv. 2021. https://doi.org/10.1101/2020.04.15.20066035
- 106. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O'Connell J, Cortes A, Welsh S, Young A, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018; 562:203–09.

https://doi.org/10.1038/s41586-018-0579-z PMID:<u>30305743</u>

- 107. Davis KA, Coleman JR, Adams M, Allen N, Breen G, Cullen B, Dickens C, Fox E, Graham N, Holliday J, Howard LM, John A, Lee W, et al. Mental health in UK Biobank - development, implementation and results from an online questionnaire completed by 157 366 participants: a reanalysis. BJPsych Open. 2020; 6:e18. <u>https://doi.org/10.1192/bjo.2019.100</u> PMID:<u>32026800</u>
- 108. Fabbri C, Hagenaars SP, John C, Williams AT, Shrine N, Moles L, Hanscombe KB, Serretti A, Shepherd DJ, Free RC, Wain LV, Tobin MD, Lewis CM. Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. Mol Psychiatry. 2021. [Epub ahead of print]. <u>https://doi.org/10.1038/s41380-021-01062-9</u> PMID:<u>33753889</u>
- 109. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, Gill JM, Roberts B, Gallacher J, Mackay D, Hotopf M, Deary I, Craddock N, Pell JP. Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. PLoS One. 2013; 8:e75362. https://doi.org/10.1371/journal.pone.0075262

https://doi.org/10.1371/journal.pone.0075362 PMID:24282498

110. Firth JA, Smith L, Sarris J, Vancampfort D, Schuch F, Carvalho AF, Solmi M, Yung AR, Stubbs B, Firth J. Handgrip strength is associated with hippocampal volume and white matter hyperintensities in major depression and healthy controls: a UK Biobank study. Psychosom Med. 2020; 82:39–46. https://doi.org/10.1097/PSY.000000000000753

PMID:<u>31702599</u>

111. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged and older adults and its association with multimorbidity and mortality: a prospective analysis of 493 737 UK Biobank participants. Lancet Public Health. 2018; 3:e323–32. https://doi.org/10.1016/S2468-2667(18)30091-4

https://doi.org/10.1016/52468-2667(18)30091 PMID:29908859

- 112. Doiron D, de Hoogh K, Probst-Hensch N, Fortier I, Cai Y, De Matteis S, Hansell AL. Air pollution, lung function and COPD: results from the population-based UK Biobank study. Eur Respir J. 2019; 54:1802140. <u>https://doi.org/10.1183/13993003.02140-2018</u> PMID:<u>31285306</u>
- 113. Said MA, Eppinga RN, Lipsic E, Verweij N, van der Harst P. Relationship of arterial stiffness index and pulse pressure with cardiovascular disease and mortality. J Am Heart Assoc. 2018; 7:e007621. <u>https://doi.org/10.1161/JAHA.117.007621</u> PMID:<u>29358193</u>
- 114. Millasseau SC, Kelly RP, Ritter JM, Chowienczyk PJ. Determination of age-related increases in large artery stiffness by digital pulse contour analysis. Clin Sci (Lond). 2002; 103:371–77. https://doi.org/10.1042/cs1030371 PMID:12241535
- 115. Wood SN. Generalized additive models: an introduction with R. 2017. https://doi.org/10.1201/9781315370279
- 116. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological). 1995; 57:289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x

SUPPLEMENTARY MATERIALS

Supplementary Material 1. CIDI-SF lifetime depression criteria.

Supplementary Table 1. Case definition lifetime depression.

	Definition and UK Biobank data fields
Lifetime depression (case): At least one core symptom of major depressive disorder, most or all of the day on most or all days for a two-week period, with at least five depressive symptoms that	("Ever had prolonged feelings of sadness or depression" (20446) = Yes OR "Ever had prolonged loss of interest in normal activities" (20441) = Yes) AND
represent a change from usual occurring over the same timescale, with some or a lot of impairment.	"Fraction of day affected during worst episode of depression" (20436) = Most of day or All day long AND
No record of psychosis or bipolar disorder.	"Frequency of depressed days during worst episode of depression" (20439) = "Almost every day" or "Every day"
	AND "Impact on normal roles during worst period of depression" (20440) = "Somewhat" or "A lot" AND
	Total number of symptoms endorsed (core and others) ≥5: "Ever had prolonged feelings of sadness or depression" (core) (20446), "Ever had prolonged loss of interest in normal activities" (core) (20441), "Feelings of tiredness during worst episode of depression" (20449), "Weight change during worst episode of depression" (20536), "Did your sleep change?" (20532), "Difficulty concentrating during worst depression" (20435), "Feelings of worthlessness during worst period of depression" (20450), "Thoughts of death during worst depression" (20437) AND No self-reported psychosis or mania for "Mental health problems ever diagnosed by a professional" (20544) AND
	 No self-reported mania/bipolar disorder/manic depression or schizophrenia for "Non-cancer illness" (20002) AND No ICD-10 code for "manic episode" or "bipolar affective disorder" (F30-F31) or "schizophrenia, schizotypal and delusional disorders" (F20-F29)
	AND No probable bipolar disorder (20126) according to Smith
	et al. (2013) AND No bipolar disorder record according to the MHQ AND
	No primary care record of bipolar disorder or psychosis

Note: Criteria for lifetime depression adapted from Davis et al. (2020), doi: 10.1192/bjo.2019.100. CIDI-SF, Composite International Diagnostic Interview Short Form; ICD-10, International Classification of Diseases, Tenth Revision; MHQ, mental health questionnaire.

Supplementary Material 2. ICD-10 codes for depression.

Depressive episode.

- F32.0 Mild depressive episode.
- F32.1 Moderate depressive episode.
- F32.2 Severe depressive episode without psychotic symptoms.
- F32.3 Severe depressive episode with psychotic symptoms.
- F32.8 Other depressive episodes.
- F32.9 Depressive episode, unspecified.

Recurrent depressive disorder.

- F33.0 Recurrent depressive disorder, current episode mild.
- F33.1 Recurrent depressive disorder, current episode moderate.
- F33.2 Recurrent depressive disorder, current episode severe without psychotic symptoms.
- F33.3 Recurrent depressive disorder, current episode severe with psychotic symptoms.
- F33.4 Recurrent depressive disorder, currently in remission.
- F33.8 Other recurrent depressive disorders.
- F33.9 Recurrent depressive disorder, unspecified.

Supplementary Material 3. Smith et al. depression criteria.

Depression (adapted from Smith et al. (2013), doi: 10.1371/journal.pone.0075362).

3. Single probable episode of major depression:

 $\frac{4598}{620}$ ever depressed/down for a whole week; plus $\frac{4609}{2100}$ at least two weeks duration; plus $\frac{4620}{00}$ only one episode, plus $\frac{2090}{2090}$ ever seen a GP or $\frac{2100}{2100}$ a psychiatrist for nerves, anxiety, depression OR

<u>4631</u> ever anhedonic (unenthusiasm/uninterest) for a whole week; plus <u>5375</u> at least two weeks; plus <u>5386</u> only one episode; plus 2090 ever seen a GP or 2100 a psychiatrist for nerves, anxiety, depression.

4. Probable recurrent major depression (moderate):

4598 ever depressed/down for a whole week; plus 4609 at least two weeks duration; plus 4620 at least two episodes; plus 2090 ever seen a GP (but not a psychiatrist) for nerves, anxiety, depression

OR

<u>4631</u> ever anhedonic (unenthusiasm/uninterest) for a whole week; plus <u>5375</u> at least two weeks; plus <u>5386</u> at least two episodes; plus <u>2090</u> ever seen a GP (but not a psychiatrist) for nerves, anxiety, depression.

5. Probable recurrent major depression (severe):

4598 ever depressed/down for a whole week; plus 4609 at least two weeks duration; plus 4620 at least two episodes; plus 2100 ever seen a psychiatrist for nerves, anxiety, depression

OR

4631 ever anhedonic (unenthusiasm/uninterest) for a whole week; plus 5375 at least two weeks; plus

5386 at least two episodes; plus 2100 ever seen a psychiatrist for nerves, anxiety, depression.

Supplementary Material 4. Psychotropic medication codes.

UK Biobank code	Drug name
1140879616	Amitriptyline
1140921600	Citalopram
1140879540	Fluoxetine
1140867878	Sertraline
1140916282	Venlafaxine
1140909806	Dosulepin
1140867888	Paroxetine
1141152732	Mirtazapine
1141180212	Escitalopram
1140879634	Trazodone
1140867876	Prozac
1140882236	Seroxat
1141190158	Cipralex
1141200564	Duloxetine
1140867726	Lofepramine
1140879620	Clomipramine
1140867818	Nortriptyline
1140879630	Imipramine
1140879628	Dothiepin
1141151946	Cipramil
1140867948	Amitriptyline
1140867624	Prothiaden
1140867756	Trimipramine
1140867884	Lustral
1141151978	Reboxetine
1141152736	Zispin
1141201834	Cymbalta
1140867690	Anafranil
1140867640	Doxepin
1140867920	Moclobemide
1140867850	Phenelzine
1140879544	Fluvoxamine
1141200570	Yentreve
1140867934	Triptafen
1140867758	Surmontil
1140867914	Tranylcypromine
1140867820	Allegron
1141151982	Edronax
1140882244	Molipaxin
1140879556	Mianserin
1140867852	Nardil
1140867860	Faverin
1140917460	Nefazodone
1140867938	Amitriptyline+Chlordiazepoxide
1140867856	Isocarboxazid
1140867922	Manerix
1140910820	Maoi
1140882312	Sinequan
1140867944	Tranylcypromine+Trifluoperazine
1140867784	Ludiomil
1140867812	Norval
1140867668	Tryptizol
1140867940*	Fluphenazine hydrochloride+Nortriptyline 1.5mg/30mg tablet
1140867942*	Fluphenazine hcl+Nortriptyline 500micrograms/10mg tablet
1140928916	Olanzapine
1141152848	Quetiapine
1140867444	Risperidone
117000/444	Kispendone

Supplementary Table 2. Psychotropic medication codes.

11 10050 (50)	
1140879658	Chlorpromazine
1140868120	Trifluoperazine
1141153490	Amisulpride
1140867304	Sulpiride
1141152860	Seroquel
1140867168	Haloperidol
1141195974	Aripiprazole
1140867244	Stelazine
1140867152	Depixol
1140909800	Flupentixol
1140867420	Clozapine
1140879746	Promazine
1141177762	Risperdal
1140867456	Modecate
1140867952	Fluanxol
1140867150	Flupenthixol
1141167976	Zyprexa
1140882100	Zuclopenthixol
1140867342	Clopixol
1140863416	Largactil
1141202024	Abilify
1140882098	Fluphenazine
1140867184	Haldol
1140867092	Serenace
1140882320	Clozaril
1140910358	Chlorpromazine
1140867208	Perphenazine
1140909802	Levomepromazine
1140867134	Pericyazine
1140867306	Dolmatil
1140867210	Fentazin
1140867398	Fluphenazine
1140867078	Benperidol
1140867218	Pimozide
1141201792	Zaponex
1141200458	Denzapine
1140867136	Neulactil
1140879750	Thioridazine
1140867180	Dozic
1140867546	Fluspirilene
1140928260	Panadeine
1140927956	Sertindole
1140867490	Lithium product
1140867494	Camcolit 250 tablet
1140867498	Liskonum 450mg m/r tablet
1140867500	Phasal 300mg m/r tablet
1140867504	Priadel 200mg m/r tablet
1140867518	Litarex 564mg m/r tablet
1140867520	Li-liquid 5.4mmol/5ml oral solution
117000/320	Er inquiti 5.4minor/5mi orai solution

Note: Adapted from Davis et al. (2019), doi: 10.1002/mpr.1796. *medication code not included in Davis et al. (2019).

Supplementary Material 5. Density plots physiological measures.



Supplementary Figure 1. Physiological measures of males and females with lifetime depression and healthy controls. Arterial stiffness truncated at 99.9th %ile. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

Supplementary Material 6. Sample characteristics.

Supplementary Table 3. Sample characteristics.

	-	Fer	nale	Male		
	Overall (N=502521)	verall (N=502521) Healthy control Depression (N=123842) (N=56276)		Healthy control (N=131212)	Depression (N=31063)	
Age						
Mean (SD)	56.53 (8.10)	55.90 (8.03)	54.74 (7.78)	56.37 (8.26)	55.71 (7.96)	
Ethnicity						
White	472711 (94.1%)	117587 (94.9%)	54386 (96.6%)	125053 (95.3%)	30089 (96.9%)	
Mixed-race	2958 (0.6%)	805 (0.7%)	434 (0.8%)	588 (0.4%)	145 (0.5%)	
Asian	8061 (1.6%)	2096 (1.7%)	556 (1.0%)	1779 (1.4%)	195 (0.6%)	
Black	9882 (2.0%)	1809 (1.5%)	459 (0.8%)	2518 (1.9%)	393 (1.3%)	
Chinese	1574 (0.3%)	527 (0.4%)	91 (0.2%)	357 (0.3%)	37 (0.1%)	
Other	4558 (0.9%)	1018 (0.8%)	350 (0.6%)	917 (0.7%)	204 (0.7%)	
Prefer not to answer	1662 (0.3%)					
Do not know	217 (<0.1%)					
Missing	898 (0.2%)					
Household income ¹	· · ·					
Very low	97205 (19.3%)	26243 (21.2%)	13986 (24.9%)	21903 (16.7%)	7181 (23.1%)	
Low	108177 (21.5%)	32464 (26.2%)	14751 (26.2%)	31452 (24.0%)	7472 (24.1%)	
Middle	110774 (22.0%)	32735 (26.4%)	14575 (25.9%)	36631 (27.9%)	8233 (26.5%)	
High	86269 (17.2%)	25352 (20.5%)	10605 (18.8%)	31999 (24.4%)	6599 (21.2%)	
Very high	22930 (4.6%)	7048 (5.7%)	2359 (4.2%)	9227 (7.0%)	1578 (5.1%)	
Prefer not to answer	49848 (9.9%)			, (, , , , , , , , , , , , , , , , ,		
Do not know	21305 (4.2%)					
Missing	6013 (1.2%)					
Walking ²	0015 (1.270)					
Mean (SD)	5.39 (1.93)	5.48 (1.84)	5.35 (1.95)	5.31 (1.99)	5.23 (2.06)	
Prefer not to answer	979 (0.2%)	5.10 (1.01)	5.55 (1.75)	5.51 (1.99)	5.25 (2.00)	
Unable to walk	1929 (0.4%)					
Do not know	6687 (1.3%)					
Missing	874 (0.2%)					
Moderate activity ²	074 (0.270)					
Mean (SD)	3.63 (2.33)	3.62 (2.31)	3.51 (2.34)	3.59 (2.31)	3.46 (2.35)	
Prefer not to answer	2273 (0.5%)	5.02 (2.51)	5.51 (2.54)	5.59 (2.51)	5.40 (2.55)	
Do not know	24120 (4.8%)					
Missing	878 (0.2%)					
Vigorous activity ²	878 (0.2%)					
• •	1.94 (1.06)	1 72 (1 95)	1 (1 (1 92)	210(202)	1.05 (2.02)	
Mean (SD)	1.84 (1.96)	1.73 (1.85)	1.61 (1.82)	2.10 (2.02)	1.95 (2.02)	
Prefer not to answer	4116 (0.8%)					
Do not know	22582 (4.5%)					
Missing	878 (0.2%)					
Smoking status	070500 (54.40()		20207 (52.00()		10050 (11.00()	
Never	273528 (54.4%)	77069 (62.2%)	30307 (53.9%)	67927 (51.8%)	13959 (44.9%)	
Former	173064 (34.4%)	37682 (30.4%)	19633 (34.9%)	49044 (37.4%)	12473 (40.2%)	
Current	52979 (10.5%)	9091 (7.3%)	6336 (11.3%)	14241 (10.9%)	4631 (14.9%)	
Prefer not to answer	2059 (0.4%)					
Missing	891 (0.2%)					
Alcohol intake frequency						
Never	40645 (8.1%)	9217 (7.4%)	4658 (8.3%)	6290 (4.8%)	2323 (7.5%)	
Special occasions	58011 (11.5%)	16310 (13.2%)	8361 (14.9%)	8259 (6.3%)	2436 (7.8%)	
1-3/month	55856 (11.1%)	15862 (12.8%)	7869 (14.0%)	11184 (8.5%)	3054 (9.8%)	
1-2/week	129294 (25.7%)	33072 (26.7%)	14017 (24.9%)	34139 (26.0%)	7516 (24.2%)	
3-4/week	115443 (23.0%)	28093 (22.7%)	11628 (20.7%)	36606 (27.9%)	7587 (24.4%)	
Daily/almost daily	101770 (20.3%)	21288 (17.2%)	9743 (17.3%)	34734 (26.5%)	8147 (26.2%)	

Prefer not to answer	605 (0.1%)				
Missing	897 (0.2%)				
Sleep duration					
Mean (SD)	7.15 (1.11)	7.18 (1.00)	7.17 (1.17)	7.13 (0.99)	7.11 (1.21)
Prefer not to answer	386 (0.1%)				
Do not know	2943 (0.6%)				
Missing	887 (0.2%)				

Note: Descriptive statistics for covariates based on main dataset N=342,393. ¹Annual household income groups: very low (<£18,000), low (£18,000–30,999), middle (£31,000–51,999), high (£52,000–100,000) and very high (>£100 000). ²number of days per week engaging in these activities for 10+ minutes continuously.

Supplementary Material 7. Adjusted GAMs.

7A. Age-related changes in females.



Supplementary Figure 2. Adjusted generalised additive models of age-related changes in physiological measures in females with lifetime depression and healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The solid lines represent physiological measures against smoothing functions of age. The shaded areas correspond to approximate 95% confidence intervals (± 2 × standard error). FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.



Supplementary Figure 3. Difference smooths comparing age-related changes in physiological measures of females with lifetime depression to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (± 2 × standard error). Negative values on the y-axes correspond to lower values in females with lifetime depression compared to healthy controls. The horizontal lines represent no difference between female cases and controls. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; Bonf, Bonferroni; BH, Benjamini and Hochberg.

7B. Age-related changes in males.



Supplementary Figure 4. Adjusted generalised additive models of age-related changes in physiological measures in males with lifetime depression and healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The solid lines represent physiological measures against smoothing functions of age. The shaded areas correspond to approximate 95% confidence intervals (± 2 × standard error). FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.



Supplementary Figure 5. Difference smooths comparing age-related changes in physiological measures of males with lifetime depression to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (± 2 × standard error). Negative values on the y-axes correspond to lower values in males with lifetime depression compared to healthy controls. The horizontal lines represent no difference between male cases and controls. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; Bonf, Bonferroni; BH, Benjamini and Hochberg.

Supplementary Material 8. Sensitivity analyses.

8A. Case-control numbers.

Deteret	Som	≥ 2 Depressio	on measures	CIDI-SF lifetime de	CIDI-SF lifetime depression (MHQ)			
Dataset	Sex	Healthy control	Depression	Healthy control	Depression			
		100040	22517	20112	20.492			
Main dataset	Female	123842	23517	30113	20482			
	Male	131212	11785	32776	9432			
Lung function	Female	43133	8010	10750	7162			
C	Male	52359	4617	13586	3826			
Bone mineral density	Female	85994	12219	19420	12907			
2	Male	89790	6075	21289	6005			
Arterial stiffness	Female	38592	11525	10818	7688			
	Male	42889	5899	11805	3528			

Supplementary Table 4. Case-control numbers sensitivity analyses.

Note: CIDI-SF, Composite International Diagnostic Interview Short Form; MHQ, mental health questionnaire.

8B. Case control differences.

		≥ 2 dej	pression m	easures		CIDI-SF lifetime depression (MHQ)				
Variable	SMD	95%	6 CI	p Bonf.	рвн	SMD	95%	6 CI	p Bonf.	<i>р</i> вн
Female										
Hand-grip strength	-0.067	-0.081	-0.053	< 0.001	< 0.001	-0.042	-0.060	-0.025	< 0.001	< 0.001
Systolic blood pressure	-0.192	-0.206	-0.178	< 0.001	< 0.001	-0.162	-0.180	-0.145	< 0.001	< 0.001
Diastolic blood pressure	-0.047	-0.061	-0.033	< 0.001	< 0.001	-0.005	-0.023	0.013	>0.999	0.600
Pulse rate	0.028	0.014	0.042	0.002	< 0.001	0.052	0.034	0.070	< 0.001	< 0.001
Body mass index	0.190	0.176	0.204	< 0.001	< 0.001	0.230	0.212	0.248	< 0.001	< 0.001
Body fat percentage	0.165	0.151	0.179	< 0.001	< 0.001	0.193	0.175	0.210	< 0.001	< 0.001
Fat mass	0.211	0.197	0.225	< 0.001	< 0.001	0.227	0.209	0.245	< 0.001	< 0.001
Fat-free mass	0.181	0.167	0.195	< 0.001	< 0.001	0.166	0.148	0.184	< 0.001	< 0.001
Waist-hip ratio	0.115	0.101	0.129	< 0.001	< 0.001	0.122	0.104	0.139	< 0.001	< 0.001
Peak expiratory flow	0.120	0.096	0.144	< 0.001	< 0.001	0.073	0.043	0.103	< 0.001	< 0.001
Forced expiratory volume 1s	0.110	0.086	0.134	< 0.001	< 0.001	0.067	0.037	0.097	< 0.001	< 0.001
Forced vital capacity	0.102	0.078	0.126	< 0.001	< 0.001	0.049	0.019	0.079	0.021	0.002
FEV ₁ / FVC	0.043	0.019	0.067	0.006	< 0.001	0.051	0.021	0.081	0.011	0.001
Heel bone mineral density	0.024	0.005	0.043	0.177	0.013	0.028	0.005	0.050	0.227	0.017
Arterial stiffness	0.007	-0.014	0.028	>0.999	0.448	0.016	-0.013	0.045	>0.999	0.301
Male										
Hand-grip strength	-0.116	-0.135	-0.097	< 0.001	< 0.001	-0.002	-0.025	0.020	>0.999	0.900
Systolic blood pressure	-0.159	-0.178	-0.140	< 0.001	< 0.001	-0.143	-0.166	-0.120	< 0.001	< 0.001
Diastolic blood pressure	-0.044	-0.063	-0.025	< 0.001	< 0.001	-0.002	-0.025	0.021	>0.999	0.900
Pulse rate	0.109	0.090	0.128	< 0.001	< 0.001	0.088	0.066	0.111	< 0.001	< 0.001
Body mass index	0.140	0.121	0.158	< 0.001	< 0.001	0.192	0.169	0.215	< 0.001	< 0.001
Body fat percentage	0.134	0.115	0.153	< 0.001	< 0.001	0.142	0.119	0.165	< 0.001	< 0.001
Fat mass	0.165	0.146	0.184	< 0.001	< 0.001	0.183	0.160	0.206	< 0.001	< 0.001
Fat-free mass	0.097	0.078	0.116	< 0.001	< 0.001	0.137	0.114	0.160	< 0.001	< 0.001
Waist-hip ratio	0.167	0.148	0.185	< 0.001	< 0.001	0.167	0.144	0.190	< 0.001	< 0.001
Peak expiratory flow	0.005	-0.025	0.035	>0.999	0.793	0.019	-0.017	0.055	>0.999	0.413
Forced expiratory volume 1s	0.003	-0.027	0.033	>0.999	0.837	0.045	0.009	0.081	0.224	0.022
Forced vital capacity	0.011	-0.019	0.041	>0.999	0.564	0.046	0.011	0.082	0.190	0.021
FEV ₁ / FVC	-0.013	-0.043	0.017	>0.999	0.517	0.006	-0.030	0.042	>0.999	0.900
Heel bone mineral density	-0.101	-0.127	-0.075	< 0.001	< 0.001	-0.074	-0.102	-0.045	< 0.001	< 0.001
Arterial stiffness	0.020	-0.007	0.047	>0.999	0.092	0.001	-0.037	0.038	>0.999	0.974

Supplementary Table 5. Differences in physiological measures between individuals with lifetime depression and healthy controls.

Note: SMD, standardised mean difference; CI, confidence interval; Bonf, Bonferroni; BH, Benjamini and Hochberg; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; CIDI-SF, Composite International Diagnostic Interview Short Form; MHQ, mental health questionnaire. *P*-values for Welch's t-test.

8C. Age-related changes in females.



Supplementary Figure 6. Difference smooths comparing age-related changes in physiological measures of females with lifetime depression (\geq 2 depression measures) to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (\pm 2 × standard error). Negative values on the y-axes correspond to lower values in females with lifetime depression compared to healthy controls. The horizontal lines represent no difference between female cases and controls. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; Bonf, Bonferroni; BH, Benjamini and Hochberg.



Supplementary Figure 7. Difference smooths comparing age-related changes in physiological measures of females with lifetime depression (CIDI-SF) to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (± 2 × standard error). Negative values on the y-axes correspond to lower values in females with lifetime depression compared to healthy controls. The horizontal lines represent no difference between female cases and controls. CIDI-SF, Composite International Diagnostic Interview Short Form; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; Bonf, Bonferroni; BH, Benjamini and Hochberg.

8D. Age-related changes in males.



Supplementary Figure 8. Difference smooths comparing age-related changes in physiological measures of males with lifetime depression (\geq 2 depression measures) to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (\pm 2 × standard error). Negative values on the y-axes correspond to lower values in males with lifetime depression compared to healthy controls. The horizontal lines represent no difference between male cases and controls. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; Bonf, Bonferroni; BH, Benjamini and Hochberg.



Supplementary Figure 9. Difference smooths comparing age-related changes in physiological measures of males with lifetime depression (CIDI-SF) to healthy controls. Models were adjusted for ethnicity (except lung function), gross annual household income, physical activity, smoking status, alcohol intake frequency, sleep duration and, for cardiovascular measures, current use of antihypertensive medications. The shaded areas correspond to approximate 95% confidence intervals (± 2 × standard error). Negative values on the y-axes correspond to lower values in males with lifetime depression compared to healthy controls. The horizontal lines represent no difference between male cases and controls. CIDI-SF, Composite International Diagnostic Interview Short Form; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; Bonf, Bonferroni; BH, Benjamini and Hochberg.